**LICENSE
      AND SUPPLY AGREEMENT**


**ERODIBLE
      ORAL MUCOADESIVE FILM BENZOCAINE**






**Dated
      as of February 6, 2007**






**between**






**DEXO
      BIOPHARM LTD.**




**and**




**ULURU
      INC.**






THIS
      LICENSE AND SUPPLY AGREEMENT (this “Agreement”) is made and entered into as of
      this 6th day of February, 2007 (the “Effective Date”), between DEXO BIOPHARM LTD
      a company incorporated under the laws of England and Wales whose registered
      office is at 15 - 17 Cambridge Science Park, Milton Road, Cambridge, CB4 0FQ,
      United Kingdom (“DEXO”) and ULURU, Inc., a corporation organized and existing
      under the laws of Nevada and having an address at 4452 Beltway Drive, Addison,
      Texas 75001 (“ULURU”).


RECITALS





WHEREAS,
      ULURU is developing a proprietary oral mucoadhesive, erodible form of drug
      that
      contains benzocaine as the active ingredient for oral pain (but excluding sore
      throat pain) as more fully described in Exhibit A attached hereto (the
“Product”), and has obtained United States Patent No. 6,585,997 in connection
      with the Product;




WHEREAS,
      DEXO possesses substantial resources and expertise in the commercialization
      and
      marketing of over-the-counter pharmaceutical products; and





WHEREAS,
      ULURU desires to grant to DEXO, and DEXO desires to obtain from ULURU, an
      exclusive license to market the Product in the Territory and an exclusive right
      to purchase from ULURU and distribute the Product in the Territory, all under
      the terms and subject to the conditions set forth herein.





NOW,
      THEREFORE, in consideration of the mutual covenants and agreements set forth
      herein, and for good and valuable consideration the receipt and sufficiency
      of
      which are hereby acknowledged, the parties hereto hereby agree as
      follows:





|1. | DEFINITIONS
|-- | -----------




|1.1. | Definitions.
|---- | ------------




As
      used
      in this Agreement, the following capitalized terms have the meanings indicated
      below:





|1.1.1. | “ULURU”
              has the meaning set forth in the
              Preamble.
|------ | ------------------------------------------------------------------------------




|1.1.2. | “ULURU
              Confidential Information” means all information, specifications
              (including, without limitation, the Specifications), know-how and data
              pertaining to the Product and ULURU’s business or its Manufacturing
              operations disclosed to DEXO or its Affiliates, Third Party manufacturers
              or distributors hereunder, including, without limitation, all information,
              Specifications, know-how and data related to the design, implementation,
              performance and manufacture of the Product, and any correspondence
              with
              the FDA or any other Regulatory Authority, clinical study data, analytical
              data, or operating procedures.
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.3. | “ULURU
              Trademark” means any trademark, trade name, trade dress, slogan, logo, or
              similar item used by ULURU prior to or as of the Effective Date, or
              subsequent to the Effective Date in connection with any ULURU product
              other than the Product.
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.4. | “Affiliate”
              means, in the case of either Party, any corporation, joint venture,
              or
              other business entity which directly or indirectly controls, is controlled
              by, or is under common control with that Party. The term “control,” as
              used in this definition, means having the power to direct, or cause
              the
              direction of, the management and policies of an entity, whether through
              ownership of voting securities, by contract or
              otherwise.
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.5. | “Batch”
              means the volume of finished, packaged Product obtained from a validated
              Manufacturing run.
|------ | -------------------------------------------------------------------------------------------------------------------------------




|1.1.6. | “Certificate
              of Analysis” means the document identifying the results of the Methods of
              Analysis for a specific Batch of Product in a form agreed to by the
              Parties in writing but which shall include, without limitation, the
              applicable Product Batch’s manufacturing date, expiration date, lot number
              and testing results and data.
|------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.7. | “Confidential
              Information” means either DEXO Confidential Information, ULURU
              Confidential Information, or both, as the context
              requires.
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.8. | “Contract
              Year” means each consecutive twelve (12) month period during the Term, the
              first of which shall commence on the first day of the calendar month
              following the date of Launch and end on the first anniversary
              thereof..
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.9. | “Control”
              means, with respect to any item of information or intellectual property
              right, the possession, whether by ownership or exclusive license, of
              the
              right to grant a license or other right with respect
              thereto.
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.10. | “Effective
              Date” has the meaning set forth in the
              Preamble.
|------- | ---------------------------------------------------------------------------------------




|1.1.11. | “Extraordinary
              Event Increase” has the meaning set forth in Section
              5.2.2.
|------- | ------------------------------------------------------------------------------------------------------




|1.1.12. | “Facility”
              means ‘s initial Third Party Manufacturing facility, and any subsequent or
              replacement Third Party Manufacturing facility identified to and approved
              by DEXO in accordance with Section 2.8.
|------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.13. | “FDA”
              means the United States Food and Drug Administration, or any foreign
              regulatory agency or government entity which fulfills a role similar
              to
              the United States Food and Drug Administration, or any successor entities
              thereto.
|------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.14. | “FD&C
              Act” means the Federal Food, Drug and Cosmetic Act, and all regulations
              promulgated thereunder, or any foreign laws, statute, rules or regulations
              fulfilling a role similar to the Federal Food, Drug and Cosmetic Act
              (and
              all regulations promulgated thereunder), as the same may be amended
              or
              supplemented from time to time.
|------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.15. | “Field”
              means the treatment of oral mouth pain utilizing anesthetics (excluding
              the treatment of sore throat).
|------- | ------------------------------------------------------------------------------------------------------------------------------------------




|1.1.16. | “Force
              Majeure Event” has the meaning set forth in Article
              10.
|------- | ------------------------------------------------------------------------------------------




|1.1.17. | “Good
              Manufacturing Practice” or “GMP” means (a) the then current standards for
              the manufacture of pharmaceuticals, as set forth in the FD&C Act, (b)
              such standards of good manufacturing practice as are required by the
              applicable laws and regulations of countries in which the Product is
              intended to be sold, to the extent such standards are not inconsistent
              with the then current standards for the manufacture of pharmaceuticals
              as
              set forth in the FD&C Act, and (c) any quality requirements set forth
              in this Agreement or the Quality Agreement attached hereto as Exhibit
              B.
|------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.18. | “Indemnified
              Party” has the meaning set forth in Section
              7.1.3.
|------- | -------------------------------------------------------------------------------------------




|1.1.19. | “Indemnifying
              Party” has the meaning set forth in Section
              7.1.3.
|------- | --------------------------------------------------------------------------------------------




|1.1.20. | “Intellectual
              Property Rights” means Patents, designs, formulae, trade secrets,
              know-how, industrial models, and technical information Controlled by
              ULURU
              and whether now existing or coming into existence during the Term and
              which are necessary for and/or related to the use or distribution of
              the
              Product.
|------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.21. | “Invention”
              means any new or useful method, process, manufacture, compound or
              composition of matter, whether or not patentable or copyrightable,
              or any
              improvement thereof arising during the Term with respect to the Product,
              its Manufacture and/or use.
|------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.22. | “Launch”
              means the date on which the Product is sold by DEXO for the first time
              to
              a Third Party for commercial distribution in the
              Territory.
|------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.23. | “Manufacture,”
              “Manufactured” or “Manufacturing” means all activities involved in the
              production of the Product, including, without limitation, the preparation,
              formulation, finishing, testing, packaging, storage and labeling of
              the
              Product and the handling, storage and disposal of any residues or wastes
              generated thereby.
|------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.24. | “Mark”
              has the meaning set forth in Section
              2.1.4.
|------- | ------------------------------------------------------------------------------




|1.1.25. | “Materials”
              means all materials, including, without limitation, all raw materials,
              ingredients, packaging supplies and labels, required for the Manufacture
              of Product.
|------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.26. | “Methods
              of Analysis” means the methods of analysis for the Product which is
              mutually agreed upon in writing between the Parties and, on a date
              to be
              mutually agreed upon by the Parties
|------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.27. | “Net
              Sales” means, with respect to the Product, the gross invoiced sales amount
              of the Product sold by DEXO or its Affiliates to non-affiliate Third
              Parties, after deduction of the following items, to the extent that
              such
              deductions are reasonable and actually allowed, taken or incurred,
              and
              (provided that such items do not exceed reasonable and customary amounts
              in the country in which the sale occurred): (a) trade and quantity
              discounts, net of any give-backs received by DEXO in return; (b) refunds,
              rebates, retroactive price adjustments, service allowances and broker’s or
              agent’s commissions; (c) credits or allowances given for rejection or
              return of previously sold Product or for wastage replacement actually
              taken or allowed; and (d) any tax, duties or government charge levied
              on
              the sale of Product and borne by DEXO and/or its Affiliates (excluding
              national, state or local taxes based on income). Such amounts shall
              be
              determined from the books and records of DEXO and its Affiliates
              maintained in accordance with generally accepted accounting principles,
              consistently applied. Sales of the Product by and between a Party and
              its
              Affiliates for further distribution to a Third Party are not sales
              to
              Third Parties and shall be excluded from Net Sales calculations for
              all
              purposes.
|------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.28. | “Party”
              or “Parties” means either DEXO, ULURU or both, as the context
              requires.
|------- | -----------------------------------------------------------------------------------------------------------




|1.1.29. | “Patents”
              shall mean (a) U.S. Patent No. 6,585,997, and (b) any and all patents,
              patent applications, patent disclosures awaiting filing determination,
              patent divisionals, continuations, continuations-in-part, reissues,
              re-examinations, renewals and extensions thereof Controlled by ULURU
              during the Term, within the Territory, which are necessary for the
              Manufacture, use or distribution of the
              Product.
|------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.30. | “Person”
              means any natural person, corporation, general partnership, limited
              partnership, limited liability company, limited liability partnership
              proprietorship, other business organization, trust, union, association
              or
              governmental authority.
|------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.31. | “PPI
              Adjustment” has the meaning set forth in Section
              5.2.
|------- | --------------------------------------------------------------------------------------




|1.1.32. | “Product”
              has the meaning set forth in the first recital
              above.
|------- | -------------------------------------------------------------------------------------------




|1.1.33. | “Recall”
              means any action by any Party to recover title to or possession of
              any
              Product sold or shipped to Third Parties or any action to prevent or
              interrupt the sale or shipment by a Party of the Product to Third Parties
              that would have been subject to recall if it had been sold or
              shipped.
|------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.34. | “Regulatory
              Approval” means all consents, permits, approvals, licenses,
              authorizations, qualifications, notices or orders that are issued or
              granted by Regulatory Authorities which are required for the manufacture,
              marketing, promotion, pricing and sale of the Product in a country
              within
              the Territory.
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.35. | “Regulatory
              Authority” shall mean all permissions which are necessary for the
              manufacture, use, marketing, distribution and sale of the Product
              including price reimbursement approval (if necessary) for the Price
              of the
              Product in any country of the Territory.
|------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.36. | “Rolling
              Forecast” has the meaning set forth in Section
              2.3.
|------- | ----------------------------------------------------------------------------------------




|1.1.37. | “Seizure”
              means any action by the FDA or any other Regulatory Authority to detain
              or
              destroy the Product or prevent the release of the
              Product.
|------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.38. | “Shortfall”
              has the meaning set forth in Section 2.6.
|------- | -------------------------------------------------------------------




|1.1.39. | “Specifications”
              means the specifications for the Product which are mutually agreed
              upon in
              writing between the Parties and, on a date to be mutually agreed upon
              by
              the Parties.
|------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.40. | “Term”
              means, with respect to the Agreement shall commence on the date of
              the
              first sale of the Product and shall continue in full force for a period
              often (10) years. Thereafter, the Agreement shall be automatically
              extended for subsequent two (2) year periods unless terminated by either
              Party in writing giving at least one hundred and eighty (180) days
              prior
              notice.
|------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.41. | “Territory”
              means, Europe including CEE (Central Eastern Europe) and CIS (Commonwealth
              of Independent States) regions and the Middle
              East.
|------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.42. | “Third
              Party” means any Person other than DEXO, ULURU and their respective
              Affiliates.
|------- | ------------------------------------------------------------------------------------------------------------------




|1.1.43. | “Trademark”
              means any trademark, trade name, trade dress, slogan, logo, or similar
              item selected by DEXO, and approved by Uluru, for use in connection
              with
              the Product.
|------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.1.44. | “DEXO”
              has the meaning set forth in the
              Preamble.
|------- | -----------------------------------------------------------------------------




|1.1.45. | “DEXO
              Confidential Information” means all information, specifications, know-how
              and data pertaining to DEXO’s business disclosed to ULURU, its Affiliates
              or its Third Party manufacturer hereunder, including, without limitation,
              marketing and sales plans, artwork, formats, equipment, logos, drawings,
              customer lists, regulatory filings, correspondence with the FDA or
              any
              other Regulatory Authority, clinical study data, analytical data,
              operating procedures and all ordering and sales
              information.
|------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.2. | Construction
              of Certain Terms and Phrases.
|---- | --------------------------------------------------------




Unless
      the context of this Agreement otherwise requires, (i) words of any gender
      include each other gender; (ii) words using the singular or plural number also
      include the plural or singular number, respectively; (iii) the terms “hereof;”
“herein,” “hereby” and derivative or similar words refer to this entire
      Agreement; (iv) the terms “Article” or “Section” refer to the specified Article
      or Section of this Agreement; and (v) Article and Section headings shall not
      affect the meaning or construction of any provision of this
      Agreement.





|2. | SUPPLY
|-- | ------




|2.1. | Grant
              of License.
|---- | -------------------------------




|1.2.1. | Subject
              to the terms and conditions of this Agreement, ULURU hereby grants
              to DEXO
              (a) the exclusive right and license in the Field to market, offer for
              sale, sell and import the Product, in the Territory, (b) the exclusive
              right and license in the Field to use the Product provided that such
              right
              and license is limited to such use as is necessary for DEXO to market,
              offer for sale, sell and import the Product in the Territory and, subject
              to the terms and conditions set forth in Section 2.6, Manufacture the
              Product in the Territory, and (c) a non-exclusive right and license
              to use
              the Product and all information and Intellectual Property Rights with
              respect thereto (including, without limitation, data, studies and clinical
              trials) solely for the purpose of obtaining Regulatory Approvals for
              the
              Product in the Territory and (d) the right to sub-license the Product
              to
              third party distributors in any country in the Territory where DEXO
              does
              not have its own marketing affiliate, subject to the written approval
              of
              ULURU, such approval not to be unreasonably withheld, Except as expressly
              granted herein, ULURU retains all rights in the Intellectual Property
              Rights and the Product.
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.2.2. | Except
              as specifically provided to the contrary in Section 2.1.1, the license
              granted in Section 2.1.1 shall not be construed (a) to effect any sale
              of
              ULURU’s Intellectual Property Rights or any other proprietary ULURU
              technology; (b) subject to the terms and conditions set forth in Section
              2.6, to grant any license relating to ULURU’s methods of formulating,
              fabricating and Manufacturing the Product; (c) to grant DEXO any rights
              in
              or to the use of the Intellectual Property Rights by implication or
              otherwise. DEXO shall mark or have marked all containers or packages
              of
              the Product in accordance with the patent marking laws of the jurisdiction
              in which such units of Product are to be used or
              distributed.
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.2.3. | Upon
              expiration of the Term, DEXO shall have a non-exclusive, fully paid
              up
              license to those licenses set forth in Section
              2.1.1.
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|1.2.4. | Subject
              to the terms and conditions of this Agreement, ULURU hereby grants
              to DEXO
              an exclusive, non-transferable (except in accordance with a permitted
              assignment of this Agreement under Section 13.3) license in the Field
              to
              use ULURU’s “ORADISC” trademark (the “Mark”) solely in connection with the
              production, marketing and sale of the Product under this Agreement,
              within
              the Territory. Based on the information provided by ULURU, DEXO
              acknowledges that ULURU is the exclusive owner of the Mark and all
              associated goodwill and registrations. DEXO agrees that it has no rights
              to use the Mark except for the right to use the Mark as provided for
              in
              this Agreement and all uses of the Mark by DEXO, and the associated
              goodwill, shall inure solely to the benefit of ULURU. DEXO further
              agrees
              that upon the termination or expiration of this Agreement, all right
              to
              use the Mark provided to DEXO hereby shall revert fully to ULURU. DEXO
              shall faithfully reproduce the Mark’s design and appearance, as such
              design and/or appearance may be modified from time to time by ULURU.
              DEXO
              shall not modify the design or appearance of the Mark unless requested
              to
              do so in writing by ULURU. If in the event of Territory requirements,
              either regulatory, legal or any other reasonable reason, DEXO may alter
              the appearance of the Mark with prior written approval from ULURU,
              which
              should not be unreasonably withheld. All uses of the Mark shall be
              subject
              to ULURU’s prior written approval on the basis of samples submitted by
              DEXO and shall be made in strict conformance with such specifications
              as
              ULURU shall establish, as such specifications may be modified by ULURU
              from time to time. All displays of the Mark shall bear such trademark
              notices as ULURU shall require. Except as consistent with this Agreement
              with respect to the Product, DEXO shall not (a) use the Mark as part
              of,
              or in conjunction with, any other names or marks without ULURU’s prior
              written approval; (b) use the Mark or any confusingly similar marks,
              terms
              or designs, except as expressly authorized in this Section 2.1.4; (c)
              attempt to register any such marks, terms or designs; (d) take any
              actions
              inconsistent with ULURU’s ownership of the Mark and any associated
              registrations, or attack the validity of the Mark, ULURU’s ownership
              thereof, or any of the terms of this Section 2.1.4; (e) use the Mark
              in
              any manner that would indicate DEXO is using such Mark other than as
              a
              licensee of ULURU; nor (f) assist any Affiliate or Third Party to do
              any
              of the same. ULURU, and/or its authorized agents or representatives,
              shall
              have the right from time to time, upon reasonable notice to DEXO, to
              inspect DEXO’s (or its contractors’) facilities and operations during
              regular business hours, that are involved in the Manufacture of the
              Product pursuant to Section 2.6; provided that such inspections shall
              be
              subject to, and ULURU shall require its authorized agents and
              representatives to agree in writing to, the confidentiality provisions
              set
              forth in Section 9 of this Agreement. Upon ULURU’s request, DEXO shall
              provide ULURU with examples of all uses of the Mark as actually used
              by
              DEXO, and a reasonable number of actual samples of the goods produced,
              marketed and sold by DEXO under the Mark. DEXO agrees to cooperate
              with
              and offer reasonable assistance to ULURU in facilitating ULURU’s control
              of the quality of the Product (and associated labels and marketing
              materials and other documentation) branded with the Mark
              hereunder.
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|2.2. | Manufacture;
              Marketing.
|---- | -------------------------------------




Subject
      to Section 2.3 and only until the execution of a definitive Manufacturing
      Agreement between the Parties, ULURU shall use commercially reasonable efforts
      to Manufacture (or cause the Manufacture) and deliver the Product to DEXO in
      such quantities, quality and at such times as ordered by DEXO in accordance
      with
      this Agreement. A condition of this License and Supply Agreement is that the
      Parties commit to negotiate a Manufacturing Agreement to transfer the
      manufacturing for the erodible oral mucoadesive film products from BioMed
      Sciences Inc., to DEXO’s manufacturing site in Tampa, Florida starting within 90
      days of signing this agreement. During the period while ULURU has responsibility
      for manufacturing, ULURU shall use commercially reasonable efforts to ensure
      that the resources necessary to manufacture the Product are available and shall
      provide, at its own expense, all Materials and labor necessary to do so. DEXO
      shall market and sell the Product in each country in the Territory; provided
      that, nothing shall require DEXO to continue to market or sell the Product
      in
      any country within the Territory during a period of time that DEXO determines,
      in its reasonable judgment, that such Product is reasonably likely to be subject
      to adverse regulatory or legal action, or infringe any intellectual property
      right of any Third Party in such country.





On
      executing this License and Supply Agreement, the Parties will work as
      expeditiously as possible to enter into a Manufacturing Agreement which will
      provide for the transfer of manufacturing to DEXO’s Tampa manufacturing site and
      find a more cost effective packaging alternative to Cardinal Healthcare. During
      this transition period, ULURU is willing to take a reduced manufacturing and
      supply margin to be mutually agreed upon. However, the Parties agree that the
      manufacturing margin lost during this period will be recouped when manufacturing
      is initiated at the DEXO manufacturing site.





|2.3. | Forecasts
              and Minimum Sales.
|---- | ------------------------------------------




At
      least
      six (6) months prior to Launch, DEXO shall submit to ULURU a forecast of the
      quantity of the Product that DEXO anticipates ordering from ULURU prior to
      DEXO’s anticipated Launch of Product and prior to DEXO’s assumption of
      Manufacturing responsibility. DEXO shall submit to ULURU a forecast of the
      quantity of the Product that DEXO anticipates ordering from ULURU (or, after
      transfer of Manufacturing, selling) during the twelve (12) month period (broken
      down by quarter) following Launch and DEXO shall update such forecast on a
      rolling twelve (12) months basis every 3 months thereafter (each, a “Rolling
      Forecast”). DEXO shall place purchase orders for at least the quantity of the
      Product specified in the first three (3) months of each such Rolling Forecast
      and the remaining nine (9) months shall be a non-binding good faith estimate.
      The orders placed should be in line with an appropriate and agreed production
      batch size. DEXO will agree minimum sales percentages of the annual sales
      forecast to be sold in each of the major markets as set forth in Exhibit
      F.





|2.4. | Orders
              and Delivery.
|---- | ----------------------------------




Prior
      to
      the transfer of Manufacturing, DEXO shall place its firm orders, either by
      writing or electronic means (fax or email) for the Product with ULURU by
      submitting a purchase order, at least ninety (90) days prior to the delivery
      date requested therein, which sets forth (a) the quantity of the Product ordered
      for delivery; and (b) the delivery date for that order. Any such purchase order
      which is in accordance with the terms and conditions of this Agreement shall
      be
      deemed to be accepted by ULURU. For all other purchase orders placed by DEXO,
      unless ULURU notifies DEXO in writing within fifteen (15) days of receipt of
      a
      purchase order that it is unable to deliver the Product in accordance with
      such
      purchase order, ULURU shall be deemed to have accepted such purchase order
      as a
      binding order. If ULURU notifies DEXO that it or its Contract Manufacturer
      is
      unable to fill a purchase order that is not in accordance with the terms and
      conditions of this Agreement, it shall indicate the portion of such purchase
      order ULURU cannot supply by the requested delivery date and specify alternate
      delivery dates; provided that in the event that DEXO delivers a purchase order
      less than ninety (90) days prior to the requested delivery date, ULURU shall
      use
      commercially reasonable efforts to meet such requested delivery date despite
      the
      shortened lead time, and ULURU will not be in breach of its obligations
      hereunder if, despite such commercially reasonable efforts, ULURU is not able
      to
      meet such requested delivery date with respect to such order. DEXO may cancel
      or
      modify any firm purchase order (in whole or in part) at any time prior to the
      delivery for any quantity of Product for which Manufacturing has not been
      completed pursuant to such purchase order at the time that notice of
      cancellation or modification is received by ULURU; provided that if
      Manufacturing has commenced but not completed pursuant to such firm purchase
      order, DEXO shall reimburse ULURU for Material and labor costs in respect of
      any
      works-in-progress pursuant to such cancelled or modified purchase order (or
      part
      thereof) at the time notice of cancellation or modification is received by
      ULURU; and provided, further, that DEXO shall reimburse ULURU for the actual,
      reasonable out-of-pocket cost of any other Material purchased by ULURU to fill
      a
      cancelled purchase order (or part thereof) that are unique to the Product and
      cannot within a reasonable period of time otherwise be used in ULURU’s or its
      Manufacturer’s operations. All Product shall be delivered Ex Works, the Facility
      and in accordance with DEXO’s instructions. Title, possession and risk of loss
      shall pass to DEXO upon delivery of Product to DEXO’s designated carrier at the
      Facility’s loading dock. The provisions of this Agreement shall prevail over any
      inconsistent statement or provisions contained in any document related to this
      Agreement passing between the parties hereto including, but not limited to,
      any
      purchase order, acknowledgment, confirmation or notice. DEXO reserve the right
      to split a manufacturing batch into different packaging in line with its
      regulatory requirements within the territory.





|2.5. | Shelf
              Life.
|---- | -------------------------




ULURU
      shall schedule Manufacturing operations so that all of the Product delivered
      has
      the latest expiry date possible, and in no event shall any Product be delivered
      to DEXO with an expiry date less than the maximum established expiry date (as
      set forth in the Specifications) less three (3) months. If Product is delivered
      to DEXO whose expiry date does not conform with the requirements set forth
      in
      this Section 2.4, ULURU shall promptly, at its sole expense, replace the
      non-conforming Product.





|2.6. | Alternative
              Supply.
|---- | ---------------------------------




Notwithstanding
      any provision herein to the contrary, in the event that (1) ULURU is in default
      of its supply obligations under this Agreement with respect to three (3)
      accepted DEXO purchase orders within any twelve month period (a “Shortfall”), or
      (2) the current manufacturing sites are deregulated, deregistered or requested
      to cease manufacture for any reason from manufacturing pharmaceutical products
      thereby restricting the sale of products to the TERRITORY or (3) if during
      Manufacture or supply of the Product to DEXO there is a material violation
      of
      the requirements set forth in Sections 2.8, 3.1, 3.2, 3.4, 3.6. 3.8 or the
      representations set forth in Sections 6.2.1, 6.2.4 or 6.2.5 (a “Regulatory
      Shortfall”) that is not cured within forty-five (45) days of the later to occur
      of the (i) date of the violation or (ii) notice to ULURU of such violation,
      then
      DEXO, in addition to any other rights and remedies it may have, shall have
      the
      right to Manufacture the Product itself and/or qualify an alternative registered
      pharmaceutical supplier of Product; provided that such right shall be subject
      to
      the parties mutually agreeing upon a royalty arrangement that would reflect
      ULURU’s lost manufacturing margin resulting from such transfer of manufacturing.
      ULURU shall, at its cost, (a) cooperate with DEXO in the transfer of copies
      of
      the Confidential Information, technology and know-how necessary to Manufacture
      the Product to DEXO and/or its designated alternative supplier, (b) deliver
      to
      DEXO copies of such drawings, specifications, and other information in ULURU’s
      possession as may be necessary to Manufacture the Product, cause the Product
      to
      be Manufactured or in order to effect a pharmaceutical marketing authorization
      within the TERRITORY and (c) grant to DEXO a limited license in the Field under
      ULURU’s Intellectual Property Rights during the Term of this Agreement to
      Manufacture, make, or have made for DEXO’s distribution of the Product in the
      Territory, the Product; provided that to the extent that such technology and
      know-how constitutes ULURU Confidential Information (or any information
      constitutes Confidential Information of ULURU’s Third Party manufacturer) it
      shall be subject to the provisions of Article 9 and DEXO’s designated
      alternative supplier shall be required to enter into a confidentiality agreement
      with ULURU containing substantially the same terms as Article 9; and further
      provided that all items provided under clauses (a) and (b) above will be subject
      to the license granted pursuant to clause (c). In addition to DEXO’s
      aforementioned right to Manufacture the Product itself and/or qualify an
      alternative supplier of the Product by reason of a Shortfall, DEXO shall be
      relieved of its obligation to order its purchase requirements of the Product
      from ULURU if ULURU, for any reason, is unable, anticipates that it will be
      unable or is unwilling to supply Product meeting DEXO’s forecasted requirements
      for a period of time of three (3) months until such ability or willingness
      to
      supply resumes; provided that DEXO shall continue to be relieved of its
      obligation to order its purchase requirements of Product from ULURU to the
      extent necessary to fulfill any reasonable contractual commitment entered into
      during such period and to the extent that it has accumulated an inventory of
      Product during such period. In the case of a Regulatory Shortfall, DEXO shall
      immediately be relieved of any obligation to order its purchase requirements
      of
      the Product from ULURU and shall not be required to purchase or accept any
      Product from ULURU until and unless the Regulatory Shortfall has been remedied.
      In the event that DEXO elects to manufacture the Product itself and/or qualify
      an alternative supplier of the Product in accordance with this Section 2.6,
      then
      ULURU shall reimburse DEXO for DEXO’s reasonable additional cost in obtaining
      and establishing an alternateive supplier. In the event of ULURU ceasing to
      be
      the manufacturer of the product ULURU commits to retain all manufacturing batch
      records for a period of seven (7) years.





|2.7. | Non-Compete.
|---- | ------------




During
      the Term, neither DEXO nor any Affiliate of DEXO may directly or indirectly
      market, offer for sale, sell, import or distribute in the Territory any human,,
      mucoadhesive, erodible disc or film product in the Field and in the form of
      the
      Product other than the Product. For the avoidance of doubt, this Agreement
      shall
      not preclude DEXO from continued development, manufacture and sale of any
      product in its own XGEL immediate  release dissolving
      film technology, offered for sale, sold, imported or distributed by DEXO as
      of
      the Effective Date.





|2.8. | Third-Party
              Manufacturer.
|---- | ---------------------------------------




ULURU
      shall, in accordance with the terms of this Section 2.8, use commercially
      reasonable efforts to establish a Manufacturing Facility (operated by a Third
      Party manufacturer) in compliance with the Regulatory Authorities requirements
      pertaining in the TERRITORY, including, without limitation, compliance with
      the
      written requirements of DEXO as provided as of the Effective Date. As of the
      Effective Date, ULURU has identified to DEXO the Third Party manufacturer it
      intends to use to Manufacture and supply to DEXO the Product and the location
      of
      the Facility. ULURU shall promptly provide DEXO with access to the Facility
      for
      inspection by DEXO. In addition, ULURU shall promptly provide DEXO with
      information requested by DEXO regarding the Third Party manufacturer (including,
      without limitation, any information requested by DEXO in accordance with DEXO’s
      due diligence, its GMP audit procedures and its “Level One Compliance
      Assessment”). During the Term and upon reasonable prior notice to ULURU, DEXO
      shall have the right, from time to time, to audit the Facility and the
      performance of the Third Party manufacturer to ensure that the Facility and
      the
      Third Party manufacturer are in compliance with GMP. Any such audits or
      inspections shall be undertaken by DEXO in accordance with the provisions of
      Section 3.5.





|2.9. | Product
              for Sale.
|---- | -------------------------------




ULURU
      and
      DEXO acknowledge and agree that, as of the Effective Date, the Product is not
      ready for sale and has to complete stability to the standard of the
      International Committee on Harmonisation (ICH) of pharmaceutical products in
      its
      final packaging material for sale sufficient to effect product registration
      and
      to maximize the product shelf life. Product for sale must include (a) the
      mutually agreed upon Methods of Analysis, and (b) the mutually agreed upon
      Specifications. ULURU shall, at its own cost and expense use commercially
      reasonable efforts to implement each of the stages in accordance with the
      applicable specifications or criteria before Launch will occur.





|2.10. | Additional
              Responsibilities.
|----- | ------------------------------------------




|2.10.1. | ULURU
              shall be responsible for (a) at ULURU’s cost and expense, supplying to
              DEXO, prior to the commencement of Manufacturing of the Product, the
              data
              reasonably requested by DEXO (including, without limitation, the final
              Product formulation, the processing requirements from start to finish
              for
              all production, the validated analytical methods, the Specifications
              and
              test method (both chemical and physical) for all elements of the disc
              component and the Product through the finished production of the Product
              and the validation protocols and schedules for processes, equipment,
              cleaning and packaging) and (b) at ULURU’s cost and expense, scale-up,
              validation and stability of the Product for commercial production of
              the
              Product, including, without limitation, production of the mucoadhesive
              disc and development and validation of a mutually acceptable package
              configuration, (c) cooperating with DEXO with respect to the obtaining
              by
              DEXO of any Regulatory Approvals required to be obtained by DEXO with
              respect to the marketing, sale, offering to sell, importing and/or
              distribution of the Product, and (d) providing to DEXO complete Batch
              records for all validation Batches and providing one copy of each full
              Batch record within 7 working days upon request.
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|2.10.2. | DEXO
              shall be responsible, at DEXO’s cost and expense, for any clinical trials,
              consumer product testing and commercialization of the Product, including,
              without limitation, all sales and marketing activities related to the
              Product and the design of all Product packaging and related artwork,
              and
              the design of all labeling.
|------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|2.10.3. | DEXO
              shall retain, at its own expense a selling and service organization
              with
              adequate experience, ability and training for purposes of marketing
              and
              selling the Product in the Territory.
|------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|2.10.4. | In
              the TERRITORY, DEXO shall be responsible at its cost for registration,
              maintenance of registration and price reimbursement approval (if
              applicable). DEXO will be furnished with chemistry, manufacturing,
              stability and technical data for regulatory approval purposes in the
              Territory. DEXO shall have the right to use and reference all technical,
              manufacturing and clinical data generated by ULURU and its licensees
              for
              such purpose. ULURU and its licensees shall have the right to use and
              reference all technical, manufacturing and clinical data generated
              by DEXO
              and its licensees. If DEXO decides not register the Product in the
              TERRITORY or any specific country in the TERRITORY, the commercial
              rights
              to the Product shall revert to ULURU. DEXO shall be the marketing
              authorization holder in the TERRITORY. Upon written approval by ULURU,
              DEXO may appoint a sub-license in certain markets where the local company
              has to remain the local marketing authorization holder due to regulatory
              requirements. This sub-license would be granted on terms similar to
              this
              agreement with specific exclusion of any manufacturing data other than
              that to effect registration.
|------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|2.11. | ULURU
              Manufacturing and Supply Obligations.
|----- | ---------------------------------------------------------




It
      is
      understood and agreed by the Parties that ULURU will be entering into an
      agreement with a Third Party manufacturer to perform the Manufacturing and
      supply obligations that ULURU has under this Agreement prior to entering into
      the Manufacturing Agreement with DEXO. In accordance with such understanding,
      ULURU acknowledges and agrees that with respect to ULURU’s obligations to DEXO
      under this Agreement (a) despite the performance by the Third Party manufacturer
      of ULURU’s Manufacturing and supply obligations hereunder, ULURU shall be fully
      responsible for the performance of such as though it were performing such
      Manufacturing and supply obligations itself, (b) all of the provisions of this
      Agreement (including, without limitation, indemnification) shall be interpreted
      in such a way as to impute any actions or omissions by the Third Party
      manufacturer to ULURU, and (c) except with respect to any matters falling within
      the scope of Section 10, ULURU shall not be relieved or excused of any of its
      obligations hereunder due to any action or failure to act by the Third Party
      manufacturer. The Third Party Manufacturer must remain fully authorized and
      regulated to carry on the manufacture of pharmaceutical products. For avoidance
      of doubt, with respect to the obligations of ULURU regarding Manufacture and
      supply to DEXO of the Product, reference to ULURU in this Agreement shall also
      mean ULURU’s contractors, Third Party manufacturer and Affiliates.





|2.12. | Marketing
              Obligations.
|----- | ------------------------------------




Following
      regulatory approval, issuance of licenses and if applicable, listing of the
      Product on the reimbursement list DEXO shall make all reasonable commercial
      efforts to Launch the Product in each country of the TERRITORY within six (6)
      months. If product launch cannot occur, DEXO can make written application to
      ULURU for an extension to the timeframe, stating its clear commercial intentions
      and the specific reasons for any delay. Such an extension will not be
      unreasonably withheld by ULURU, but any such extention granted may be limited
      in
      time by ULURU. DEXO and its distributors shall use reasonable commercial efforts
      to promote the commercialization and sales of the Product, subject to compliance
      with all applicable laws and regulations to promote and market the Product.
      DEXO
      and its distributors shall maintain a competent marketing and sales organization
      in the TERRITORY. If DEXO decides not to, or is unable to, Launch the Product
      in
      the TERRITORY or a specific country in the TERRITRORY under the terms as laid
      out in 2.12, the commercial rights in relation to that country to the Product
      shall revert to ULURU.





|2.13. | Marketing
|----- | ---------




DEXO
      shall have sole responsibility for marketing the Product in the TERRITORY.
      In
      countries in the TERRITORY where DEXO does not have its own marketing affiliate,
      DEXO will have the right to appoint third party distributors subject to the
      written approval of ULURU, such approval not to be unreasonably withheld. DEXO
      shall furnish ULURU with written reports twice a year in the major markets
      listed in Exhibit F, covering the market share of the Product, business trends
      and key marketing issues relating to the Product.





|3. | COMPLIANCE,
              QUALITY AND ENVIRONMENTAL
|-- | ---------------------------------------------------




|3.1. | Compliance
              with Law.
|---- | ----------------------------------




ULURU
      shall use commercially reasonable efforts to cause its contract manufacturer
      to
      conduct all Manufacturing hereunder in a safe and prudent manner, in compliance
      with all applicable laws and regulations (including, without limitation, those
      dealing with occupational safety and health, those dealing with public safety
      and health, those dealing with protecting the environment, and those dealing
      with disposal of wastes), and in compliance with all applicable provisions
      of
      this Agreement. ULURU shall obtain and maintain all necessary Regulatory
      Approvals with respect to the Manufacture and supply to DEXO of the Product.
      To
      the extent necessary for the Regulatory Approval of the Product, ULURU, shall
      permit the inspection of its premises and the Facility by Regulatory Authorities
      and shall supply all documentation and information requested by DEXO or such
      Regulatory Authority to obtain or maintain Regulatory Approval of the
      Product.





|3.2. | Manufacturing
              Quality; Storage.
|---- | ---------------------------------------------




All
      Product shall be Manufactured by ULURU’s contract manufacturer at the Facility
      using Materials and processing aids free of animal derived materials. ULURU
      shall sample and analyze all Materials upon receipt to ensure that such
      Materials are unadulterated, free of defects and meet the applicable
      Specifications therefor. ULURU shall take all necessary steps to prevent
      contamination and cross contamination of Product. The Product shall be
      unadulterated and free from contamination, dilutents and foreign matter in
      any
      amount in accordance with the Product specifications and generally accepted
      pharmaceutical standards. ULURU shall perform the quality control tests (both
      when the Product is in-process and when it is finished) with respect to the
      Product in accordance with the Methods of Analysis, the cost of such to be
      included in the price hereinafter specified. ULURU shall promptly, upon
      completion of such tests, deliver to DEXO a copy of the record of such tests
      performed on, and a Certificate of Analysis for, each Batch of Product. ULURU
      shall deliver a representative sample from each Batch of Product to DEXO’s
      designated representative by the date reasonably specified by such
      representative. Within thirty (30) days of the Effective Date, each of the
      Parties shall execute and deliver the Quality Agreement substantially in the
      form of Exhibit B and as mutually agreed to by the parties. Each Party agrees
      to
      perform its respective obligations under the Quality Agreement in accordance
      with such agreement. Prior to shipment, the Product shall be stored at all
      times
      in conditions at least as favorable as those set forth on the Product’s label,
      or in accordance with conditions reasonably specified by DEXO.





|3.3. | Testing
              by DEXO.
|---- | ------------------------------




DEXO
      may
      test the Product samples in accordance with the applicable Methods of Analysis.
      If the analysis of any Product performed by or for DEXO differs from ULURU’s
      analysis of the same Batch, DEXO shall advise ULURU and ULURU and DEXO agree
      to
      consult with each other in order to explain and resolve the discrepancy between
      each other’s determination. If, after good faith attempt by the Parties to do
      so, such consultation does not resolve the discrepancy, an independent,
      reputable laboratory as mutually agreed by the Parties shall repeat the
      applicable Methods of Analysis on representative samples from such Batch
      provided by both ULURU and DEXO. The costs of the independent laboratory
      referred to above shall be borne by (a) DEXO if such laboratory determines
      that
      the Product conforms to the Specifications or (b) ULURU if such laboratory
      determines that the Product does not conform to the Specifications. If so
      requested by DEXO in writing, ULURU shall promptly send a new Batch of the
      Product (of similar quantity as to the amount of such Product being analyzed
      as
      set forth above) to DEXO. DEXO shall not be obligated to pay for any of the
      Product (and if DEXO has paid for such Product ULURU shall promptly reimburse
      DEXO for the cost of replacing such Product, including, without limitation,
      related costs such as testing and transportation costs) that such laboratory
      determines does not conform to the Specifications, but shall be obligated to
      pay
      for any new Batch of Product that is sent as specified above; provided that
      DEXO
      must destroy (and certify destruction of) such nonconforming
      Product.





|3.4. | Samples
              and Record Retention.
|---- | -------------------------------------------




ULURU
      shall retain records and retention samples of each Batch of the Product for
      at
      least seven years after the manufacturing date of that Batch and shall make
      the
      same available to DEXO upon request. Retention samples shall only be destroyed
      after the required holding period; provided that in the event that DEXO provides
      written notice to during and after the Term of this Agreement ULURU shall
      reasonably assist DEXO with respect to any complaint, issue or investigation
      relating to the Product.3





|3.5. | Inspection.
|---- | -----------




ULURU
      shall give access to representatives of DEXO, at all reasonable times during
      regular business hours, to the Facility and any other facility in which Product
      is Manufactured, tested, packaged and/or stored, and to all Manufacturing
      records with respect to the Product, for the purpose of inspection. DEXO shall
      have the right while at any such Facility to inspect and copy, provided that
      to
      the extent that such copies constitute ULURU Confidential Information (or
      Confidential Information of ULURU’s Third Party Manufacturer) they shall be
      subject to the provisions of Article 9, records and Regulatory Approvals solely
      to evaluate work practices and compliance with all applicable FDA and other
      Regulatory Authority laws and regulations, occupational health and safety,
      and
      environmental laws and regulations, GMP and warehousing practices and
      procedures. The conduct of(or right to conduct) any inspection under this
      Section 3.5 does not impose upon DEXO responsibility or liability for the
      operation of the Facility.


Such
      inspection shall be conducted after prior written notice to ULURU, will be
      conducted consistently with the DEXO policies and procedures provided to ULURU
      as of the Effective Date (and as such policies and procedures are modified
      and
      provided in writing to ULURU from time to time, which modified policies and
      procedures shall not conflict with any of the provisions of this Agreement)
      and
      in a manner that is not disruptive to ULURU’s or its contract manufacturer’s
      operations, and shall not be more frequent than is reasonable.





|3.6. | Adverse
              Drug Experience Reporting
|---- | -----------------------------------------------




Each
      Party shall fully, accurately and promptly provide the other Party with all
      data
      known to it at any time during the Term of this Agreement or thereafter, which
      data indicate that any Product is or may be unsafe, lacks utility, or otherwise
      does not meet the Specifications in accordance with the Adverse Event Reporting
      Procedures set forth in Exhibit C attached hereto (as the same may be amended
      from time to time by notice in writing from DEXO to ULURU; provided that such
      amendment shall not conflict with any of the provisions of this Agreement).
      DEXO
      shall determine whether such information is required to be reported to the
      FDA
      and any other Regulatory Authority.





|3.7. | Recalls
              and Seizure.
|---- | ----------------------------------




|3.7.1. | Each
              Party shall keep the other Party promptly and fully informed of any
              notification or other information whether received directly or indirectly
              which might result in the Recall or Seizure of the Product. If either
              Party determines that it is necessary to Recall any Product, it shall
              immediately notify the other Party and, prior to commencing any Recall,
              the Parties shall consult with one another to determine whether or
              not a
              Recall is necessary. If it is mutually agreed that a Recall is necessary,
              then the parties shall meet and determine the manner in which the Recall
              is to be carried out and review any instructions or suggestions of
              the
              applicable Regulatory Authorities. ULURU and DEXO shall effect the
              Recall
              in the manner agreed upon between the Parties in as expeditious a manner
              as possible and in such a way as to cause the least disruption to the
              sales of any Product and to preserve the goodwill and reputation
              associated with the Product.
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|3.7.2. | In
              the event that a Recall results from any cause or event arising from
              ULURU’s breach of Sections 2.8, 3.1, 3.2, 3.4, 3.6. 3.8 or the
              representations set forth in Sections 6.2.1, 6.2.4 or 6.2.5 and/or
              the
              defective Manufacture, storage or handling of the Product by ULURU
              (excluding defects relating to packaging or labeling supplied by or
              prepared at and in accordance with the direction of DEXO), ULURU shall
              be
              responsible for all expenses of the Recall incurred by DEXO and ULURU
              shall promptly replace such Product at no additional cost to DEXO
              consistent with directions received from the appropriate Regulatory
              Authority. In the event that a Recall results from any cause or event
              arising from defective Manufacture, storage, handling, or distribution
              of
              the Product by DEXO or its Affiliates, distributors or contractors
              (including but not limited to defective Manufacture, storage, handling
              or
              distribution undertaken at the direction of DEXO and consistently with
              DEXO’s instructions), DEXO shall be responsible for the expenses of the
              Recall, including the cost of replacement Product. For the purposes
              of
              this Agreement, the expenses of a Recall shall include, without
              limitation, the expenses of notification and destruction or return
              of the
              recalled Product and all other costs incurred in connection with such
              Recall, including reasonable costs and attorneys’ fees, but shall not
              include lost profits of either party.
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|3.8. | Environmental,
              Occupational Health and Safety.
|---- | ------------------------------------------------------------




|3.8.1. | ULURU
              shall promptly report to DEXO after any of the following incidents
              related
              to the Manufacturing operations hereunder occurs: (a) fatalities and/or
              significant injuries or occupational illness; (b) property damage in
              excess of $50,000; (c) inspections by any environmental protection
              agency
              or occupational health and safety agency; or (d) requests for information,
              notices of violations or other significant governmental and safety
              agency
              communications relating to environmental, occupational health and safety
              compliance.
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|3.8.2. | As
              between ULURU and DEXO, LILURU shall have title to and be responsible
              for
              disposing in an environmentally safe manner all residue and waste
              resulting from the Manufacturing operations performed hereunder. ULURU
              shall not use DEXO trademarks or trade dress to identify any waste
              materials or residues.
|------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|4. | MANUFACTURING
              CHANGES
|-- | -----------------------------------




|4.1. | Voluntary
              Change
|---- | ------------------------------




ULURU
      shall not make, nor shall any other Person make, any changes to the
      Manufacturing process, the Manufacturing equipment, the Specifications, the
      Materials, the sources of Materials or the Methods of Analysis without the
      prior
      written consent of DEXO. If either Party requests in writing a change in the
      Manufacturing process, the Manufacturing equipment, the Specifications, the
      Materials, the source of Materials or Methods of Analysis with respect to the
      Product that is not the result of a requirement of the FDA or any other
      Regulatory Authority, the other Party shall use commercially reasonable efforts
      to make or accept such change, as the case may be. The requesting Party shall
      provide the other Party with a detailed written report of all proposed changes
      to the Manufacturing process, the Manufacturing equipment, the Specifications,
      the Materials, the sources of Materials or the Methods of Analysis.





|4.2. | Required
              Changes.
|---- | -------------------------------




If
      any of
      the Regulatory Authorities requests or requires, or takes any action that
      requires, any change in the Manufacturing process, the Manufacturing equipment,
      the Specifications, the Materials, the source of Materials or Methods of
      Analysis with respect to the Product, the Parties shall meet and discuss an
      implementation plan for such change and use commercially reasonable efforts
      to
      accommodate as soon as practicable such change to meet the Regulatory
      Authority’s requirements. Each Party will bear its respective costs associated
      with, or incurred as a result of, such change. Each Party agrees to promptly
      forward to the other copies of any written communication received by such Party
      from the Regulatory Authority that may affect the Manufacture, supply, or
      distribution of the Product as contemplated herein.





|5. | PRICE
              AND PAYMENT
|-- | -------------------------------




|5.1. | Price.
|---- | ------




ULURU
      shall invoice DEXO for the Product supplied to DEXO hereunder at the applicable
      price per Product set forth on Exhibit D. The supply price of Product shall
      remain in effect unless and until the price of the Product is adjusted pursuant
      to this Article 5.





|5.2. | Price
              Adjustment.
|---- | -------------------------------




|5.2.1. | Commencing
              on any date in the second Contract Year, ULURU may adjust the then-current
              price to reflect documented increases or decreases in labor costs,
              variable overhead costs or the acquisition cost of Materials per unit
              of
              Product at the beginning of the Contract Year in question as compared
              to
              the acquisition cost of such labor, variable overhead or Materials
              per
              unit of Product at the beginning of the immediately preceding Contract
              Year; provided that ULURU gives DEXO not less than ninety (90) days’ prior
              written notice of any price increase or decrease and that ULURU may
              not
              increase the price more than once during any Contract Year; and provided,
              further, that except as provided in Section 5.2.2, any price increase
              per
              unit of Product shall not exceed the PPI Adjustment for the Contract
              Year
              in question. Until the effective date of such price increase, ULURU
              shall
              supply DEXO such Product at the prices then in effect without such
              price
              increase. “PPI Adjustment” means for the Contract Year in question, the
              amount calculated in accordance with the following
              formula;
|------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MC
      x PPI
      - BPPI


BPPI





Where,





MC=
            the
                documented labor costs, variable overhead costs and the acquisition
                cost
                of all Materials per unit of Product at the beginning of the Contract
                Year
                immediately preceding the Contract Year in question;BPPI=
            the
                Bureau of Labor Statistics Producer’s Price Index for Pharmaceutical
                Preparations (Code 2834) for the first month of the Contract Year
                immediately preceding the Contract Year in question;
                andPPI=
            the
                Bureau of Labor Statistics Producer’s Price Index for Pharmaceutical
                Preparations (Code 2834) for the first month of the Contract Year
                in
                question.





Notwithstanding
      anything to the contrary contained in this Section 5.2.1, there shall be no
      price increases made due to any increases with respect to the fixed overhead
      component of the cost of the Product.





|5.2.2. | Notwithstanding
              anything to the contrary in Section 5.2.1, in the event of an
              extraordinary event that results in a documented material increase
              (with
              “material increase” meaning, for purposes of this Section 5.2.2, an
              increase of at least fifteen (15%) percent in the aggregate) in the
              collective cost of a major component of Manufacturing for the Product
              during any annual period after the end of the first Contract Year (an
              “Extraordinary Event Increase”), ULURU need not wait until the next annual
              period to adjust the pricing for the Product. Upon ULURU’s determination
              that an Extraordinary Event Increase has occurred, ULURU shall notify
              DEXO
              in writing of the applicable price adjustment, together with supporting
              documentation evidencing such change including without limitation,
              evidence that ULURU shall have used its commercially reasonable efforts
              to
              secure alternative sources of supply for any components or consumables,
              at
              lesser costs without detracting from the quality or efficacy of the
              Product. Any such pricing adjustment will become effective thirty (30)
              days following the date of ULURU’ s written notice
              thereof.
|------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|5.3. | Continuous
              Improvement Price Adjustment.
|---- | ------------------------------------------------------




Continuous
      improvement initiatives, mutually agreeable to the Parties shall be established
      annually to provide for attempting to achieve continuous cost reductions during
      the Term hereof. Continuous improvement teams consisting of equal representation
      from each Party shall use reasonable efforts to work to identify and implement
      cost savings at a targeted rate of five percent (5%) of DEXO’s purchase price
      per Contract Year. Any documented savings shall be allocated to the Parties
      equally once production has been transferred to DEXO. Any cost savings allocated
      to DEXO shall be in the form of reduced purchase price, effective (with respect
      to any subsequent DEXO purchase orders) immediately upon documentation and
      allocation of the savings.





|5.4. | License
              Payments.
|---- | -------------------------------




DEXO
      shall notify ULURU in writing within fifteen (15) days of each license fee
      milestone event and make the appropriate payment to ULURU in US dollars within
      thirty (30) days of the occurrence of the applicable milestone set forth in
      Exhibit E.





|5.5. | Royalty
              and Royalty Payments.
|---- | -------------------------------------------




In
      addition to the payments set forth above, where DEXO out-licenses the Product
      in
      specific countries in the Territory where it does not have its own marketing
      affiliate, ULURU will receive fifteen (15%) per cent of all royalty and
      licensing or other payments DEXO receives from sub-licensees. DEXO shall pay
      the
      Royalty with respect to a country that accrues during the Term of this Agreement
      for so long as the license granted by ULURU under Section 2.1.1 remains in
      effect in such country. DEXO will include with each such payment a written
      report detailing (i) the number of Product units, per country, and the sales
      price of such Product units by DEXO and its Affiliates; and (ii) Net Sales
      of
      the Product during the applicable Royalty Period, all in a manner consistent
      with DEXO’s internal sales reporting. Royalty payments shall be paid to ULURU in
      US dollars thirty (30) days following the close of the calendar quarter at
      the
      relevant spot exchange rate published in the London Financial Times at the
      end
      of the calendar quarter.





|5.6. | Payment
              for Product
|---- | ---------------------------------




DEXO
      shall pay invoices for Product delivered hereunder not later than thirty (30)
      days after the later of receipt of Product covered by such invoice and receipt
      of such invoice.





|5.7. | Taxes
              and Other Charges.
|---- | --------------------------------------




All
      Product prices are exclusive of taxes, shipping costs to the point of delivery,
      customs duties and other charges, and DEXO agrees to bear and be responsible
      for
      the payment of all such charges imposed, excluding taxes based upon ULURU’s net
      income.





|5.8. | Audit
              Rights.
|---- | ---------------------------




|5.8.1. | DEXO
              shall have the right, at its own expense, to access the books and records
              of ULURU and its Affiliates as may be reasonably necessary to verify
              the
              accuracy of the labor costs and Material costs referred to in Section
              5.2.
              Such access shall be conducted after thirty (30) days’ prior written
              notice to ULURU and during ordinary business hours, will be conducted
              in a
              manner that is not disruptive to ULURU’s operations, and shall not be more
              frequent than once per Contract Year. Subject to Section 5.8.3, if
              such
              independent certified public accountant’s report shows any overpayment by
              DEXO, ULURU shall remit to DEXO within thirty (30) days after ULURU’s
              receipt of such report, (a) the amount of such overpayment, and (b)
              if
              such overpayment exceeds five percent (5%) of the total amount owed
              for
              the period then being audited, the reasonable fees and expenses of
              any
              independent accountant performing the audit on behalf of DEXO. Subject
              to
              Section 5.8.3, if such independent certified public accountant’s report
              shows any underpayment by DEXO, DEXO shall pay to ULURU within thirty
              (30)
              days after DEXO’s receipt of such report, the amount of such underpayment.
              Any audit or inspection conducted under this Agreement by DEXO or its
              agents or contractors will be subject to the confidentiality provisions
              of
              this Agreement, and DEXO will be responsible for compliance with such
              confidentiality provisions by such agents or
              contractors.
|------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|5.8.2. | DEXO
              shall maintain books of account with respect to its sales of the Product
              each country in the Territory. ULURU shall have the right, not more
              than
              once during each calendar year, to have an independent accountant selected
              and retained by ULURU to inspect and examine such books of DEXO during
              regular business hours for the purpose of verifying the statements
              of the
              aggregate Net Sales resulting from sales of Product and determining
              the
              correctness of the Royalties, milestones or up-front payments paid.
              Subject to Section 5.8.3, if such independent certified public
              accountant’s report shows any underpayment by DEXO, DEXO shall pay to
              ULURU within thirty (30) days after DEXO’s receipt of such report, (a) the
              amount of such underpayment, and (b) if such underpayment exceeds five
              percent (5%) of the total amount owed for the period then being audited,
              the reasonable fees and expenses of any independent accountant performing
              the audit on behalf of UTJJRU. Subject to Section 5.8.3, such independent
              certified public accountant’s report shows any overpayment by DEXO, ULURU
              shall remit to DEXO within thirty (30) days after ULURU’s receipt of such
              report, the amount of such overpayment. Any audit or inspection conducted
              under this Agreement by ULURU or its agents or contractors will be
              subject
              to the confidentiality provisions of this Agreement, and ULURU will
              be
              responsible for compliance with such confidentiality provisions by
              such
              agents contractors.
|------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|5.8.3. | If
              any dispute arises under this Section 5.8 between the Parties relating
              to
              overpayments or underpayments, and the Parties cannot resolve such
              dispute
              within thirty (30) days of a written request by either Party to the
              other
              Party, the Parties shall hold a meeting, attended by the Chief Executive
              Officer or President of each party (or their respective designees),
              to
              attempt in good faith to negotiate a resolution of the dispute. If,
              within
              sixty (60) days after such meeting request, the Parties have not succeeded
              in negotiating a resolution of the dispute, either Party may pursue
              any
              other available remedy, including, upon prior written notice to the
              other
              Party, instituting legal action.
|------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|5.9. | Late
              Payments.
|---- | ----------------------------




If
      any
      payment due to ULURU under this Agreement is not received by ULURU within ten
      (10) days of the due date, then, commencing from the date on which such payment
      was due the amount of such payment shall accrue interest calculated at an annual
      rate equal to the prime rate plus two percent (2%) until such time as payment
      of
      the overdue amount is made in frill; provided that no interest shall accrue
      on
      any amounts being disputed in good faith by DEXO with respect to which DEXO
      is
      making diligent and good faith efforts to resolve.





|5.10. | Currency
              Exchange.
|----- | --------------------------------




All
      payments to be made pursuant to this Agreement shall be made in United States
      dollars. Amounts based on Net Sales in currencies other than United States
      dollars shall be converted on the last business day of each calendar month
      to
      United States dollars at the DEXO financial statement exchange rate applied
      by
      DEXO on a consistent basis in DEXO’s own financial accounting.





|6. | REPRESENTATIONS
              AND WARRANTIES
|-- | --------------------------------------------




|6.1. | Representation
              and Warranties of Each Party.
|---- | ----------------------------------------------------------




Each
      of
      DEXO and ULURU hereby represents, warrants and covenants to the other Party
      hereto as follows:





|6.1.1. | it
              is a corporation or entity duly organized and validly existing under
              the
              laws of the state or other jurisdiction of incorporation or
              formation;
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.1.2. | the
              execution, delivery and performance of this Agreement by such Party
              has
              been duly authorized by all requisite corporate action and do not require
              any shareholder action or approval;
|------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.1.3. | it
              has the power and authority to execute and deliver this Agreement and
              to
              perform its obligations hereunder;
|------ | --------------------------------------------------------------------------------------------------------------------------------------------------------




|6.1.4. | the
              execution, delivery and performance by such Party of this Agreement
              and
              its compliance with the terms and provisions hereof does not and will
              not
              conflict with or result in a breach of any of the terms and provisions
              of
              or constitute a default under (a) a loan agreement, guaranty, financing
              agreement, agreement affecting a product or other agreement or instrument
              binding or affecting it or its property; (b) the provisions of its
              charter
              or operative documents or by laws; or (c) any order, writ, injunction
              or
              decree of any court or governmental authority entered against it or
              by
              which any of its property is bound; and
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.1.5. | it
              shall comply with all applicable laws and regulations relating to its
              activities under this Agreement.
|------ | -------------------------------------------------------------------------------------------------------------------------------------




|6.2. | Representations
              and Warranties of ULURU.
|---- | ------------------------------------------------------




ULURU
      hereby further represents and warrants to DEXO that:





|6.2.1. | as
              of the date of each delivery of the Product by ULURU to a carrier,
              the
              Product (a) has been Manufactured, stored and shipped in strict accordance
              with GMPs, all applicable laws, rules, regulations or requirements
              and all
              applicable Regulatory Approvals in effect at the time of Manufacture;
              (b)
              conforms to the Specifications and the Quality Agreement, and is free
              from
              defects and are merchantable; (e) is not adulterated or misbranded;
              and
              (d) has been shipped and stored in accordance with procedures requested
              by
              DEXO;
|------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.2.2. | as
              of the date of each delivery of the Product by ULURU to a carrier,
              ULURU
              has good and marketable title to the Product and the Product is free
              from
              all liens, charges, encumbrances and security
              interests;
|------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.2.3. | to
              ULURU’s actual knowledge as of the Effective Date, the Manufacture, use,
              importation, offer for sale and sale of the Product does not infringe
              any
              intellectual property rights of any Third Party within the
              Territory;
|------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.2.4. | as
              of the date of each delivery of the Product by ULURU to a carrier,
              neither
              ULURU not any Affiliate, contractor or Third Party manufacturer of
              ULURU,
              used or uses in any capacity the services of any person debarred under
              the
              U.S. Generic Drug Enforcement Act, 21 USA §335a(k)(l) and further it did
              not use any person who has been convicted of a crime as defined under
              the
              Generic Drug Enforcement Act in connection with the Manufacture of
              Product;
|------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.2.5. | as
              of the date of each delivery of the Product by ULURU to a carrier,
              ULURU
              possesses all necessary Regulatory Approvals relating to ULURU’s
              Manufacture and supply to DEXO of the
              Product;
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.2.6. | as
              of the Effective Date, U.S. Patent No. 6,585,997 is existing and has
              not
              been held to be invalid or unenforceable, in whole or in
              part;
|------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.2.7. | as
              of the Effective Date, ULURU is the sole and exclusive owner of the
              Intellectual Property Rights existing as of the Effective Date, all
              of
              which are free and clear of any liens, charges and encumbrances (other
              than any licenses granted by ULURU to Third Parties, which grants do
              not
              conflict with the license grants to DEXO
              hereunder);
|------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|6.2.8. | as
              of the Effective Date, and, except as disclosed to DEXO in writing,
              as of
              the date of each delivery of the Product by ULURU to a carrier, ULURU
              has
              received no notice that the practice of the Intellectual Property Rights
              or the Mark are subject to an infringement claim of any issued patent
              or
              Mark owned or possessed by any Third Party within the
              Territory;
|------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.2.9. | as
              of the Effective Date, the Intellectual Property Rights are not the
              subject to any funding agreement with any government or governmental
              agency; and
|------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.2.10. | as
              of the Effective Date, or within ten (10) days thereof, ULURU has provided
              DEXO with any and all information relating to the Product, its Manufacture
              and formulation necessary for DEXO to conduct a freedom to operate
              opinion
              relating to the Territory, and all information has been provided so
              that
              DEXO may complete its due diligence.
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.3. | No
              Presumption.
|---- | -----------------------------




Each
      Party hereto represents that it has been represented by legal counsel in
      connection with this Agreement and acknowledges that it has participated in
      the
      drafting hereof. In interpreting and applying the terms and provisions of this
      Agreement, the Parties agree that no presumption shall exist or be implied
      against the Party which drafted such terms and provisions.





|6.4. | Remedy.
|---- | -------




As
      DEXO’s
      sole and exclusive remedy for any breach of Section 6.2.1 discovered prior
      to
      the distribution by DEXO or its Affiliates of the applicable Product, ULURU
      shall promptly replace, at its sole cost and expense, any Product which fails
      to
      comply with the representations set forth in Section 6.2.1; provided that such
      nonconforming Product shall be returned to ULURU in accordance with ULURU’s
      return procedures, and only if after ULURU’s inspection, such Product is
      determined to have been non-conforming pursuant to the procedures set forth
      in
      Section 3.3. Except as otherwise provided expressly in this Agreement, each
      Party is free to seek legal and equitable recourse against the other in the
      event of any breach of this Agreement (including, without limitation, any breach
      of such other Party’s obligations, representations, or warranties under this
      Agreement), subject to the limitations of liability set forth in Section 6.7
      and, in such case, the breaching party shall be liable for all damages, losses,
      liabilities, expenses or penalties (excluding attorneys’ fees and expenses)
      incurred, assessed or sustained by or against the non-breaching party, its
      Affiliates, directors, officers, employees or agents arising out of such
      breach.





|6.5. | DEXO
              Responsibility.
|---- | ----------------------------------




DEXO
      shall not be responsible for any loss or cost incurred by ULURU during
      Manufacture of the Product in compliance with the requirements of Section
      6.2.1.





|6.6. | Disclaimer.
|---- | -----------




|6.6.1. | THE
              FOREGOING WARRANTIES ARE THE SOLE AND EXCLUSIVE WARRANTIES GIVEN BY
              ULURU
              WITH RESPECT TO THE PRODUCTS AND SERVICES PROVIDED HEREUNDER, AND ULURU
              GIVES AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS
              OR
              IMPLIED, OTHER THAN THE FOREGOING. WITHOUT LIMITING THE GENERALITY
              OF THE
              FOREGOING, EXCEPT FOR THE WARRANTIES EXPRESSLY PROVIDED IN SECTION
              6, NO
              IMPLIED WARRANTY OF MERCHANTABILITY, VALIDITY, NONINFRINGEMENT, TITLE,
              FITNESS FOR ANY PARTICULAR PURPOSE, AND NO IMPLIED WARRANTY ARISING
              BY
              USAGE OF TRADE, COURSE OF DEALING OR COURSE OF PERFORMANCE IS GIVEN
              OR
              MADE BY ULURU OR SHALL ARISE BY OR IN CONNECTION WITH ANY SALE OR
              PROVISION OF PRODUCTS OR SERVICES BY ULURU, OR DEXO’S USE OR SALE OF THE
              PRODUCT, OR ULURU’S AND/OR DEXO’S CONDUCT IN RELATION THERETO OR TO EACH
              OTHER. NO REPRESENTATIVE OF ULURU IS AUTHORIZED TO GIVE OR MAKE ANY
              OTHER
              REPRESENTATION OR WARRANTY OR TO MODIFY THE FOREGOING WARRANTY IN ANY
              WAY
|------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.6.2. | EXCEPT
              FOR THE WARRANTIES GIVEN BY DEXO AS EXPRESSLY PROVIDED IN SECTION 6,
              DEXO
              GIVES AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE,
              EXPRESS OR IMPLIED, WITH RESPECT TO THE MATTERS ADDRESSED IN THIS
              AGREEMENT.
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.6.3. | The
              warranties set forth in this Section 6 do not apply to any nonconformity
              of the Product resulting from (a) repair, alteration, misuse, negligence,
              abuse, accident, mishandling or storage in an improper environment
              by any
              party other than ULURU (or its contract manufacturer), or (b) use,
              handling, storage or maintenance other than in accordance with Product
              Specifications or Product label.
|------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|6.7. | Limitation
              of Liability.
|---- | --------------------------------------




ULURU’S
      LIABILITY, AND THE EXCLUSIVE REMEDY, IN CONNECTION WITH THE SALE OR USE OF
      THE
      PRODUCT (WHETHER BASED ON CONTRACT, NEGLIGENCE, BREACH OF WARRANTY, STRICT
      LIABILITY OR ANY OTHER LEGAL THEORY), SHALL BE STRICTLY LIMITED TO ULURU’S
      OBLIGATIONS AND DEXO’S RIGHTS AS SPECIFICALLY AND EXPRESSLY PROVIDED IN THIS
      AGREEMENT.





IN
      NO
      EVENT WHATSOEVER SHALL EITHER PARTY HAVE ANY LIABILITY, OBLIGATION OR
      RESPONSIBILITY TO THE OTHER PARTY OR SUCH OTHER PARTY’S AFFILIATES FOR ANY
      INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES
      ARISING IN ANY WAY IN CONNECTION WITH PRODUCT OR ITS PURCHASE, SALE, USE OR
      INABILITY TO USE.





|7. | INDEMNIFICATION
              AND INSURANCE
|-- | -------------------------------------------




|7.1. | Indemnification.
|---- | ----------------




|7.1.1. | ULURU
              shall defend, indemnify and hold harmless DEXO, its Affiliates, directors,
              officers, employees and agents from and against all damages, losses,
              liabilities, expenses, claims, demands, suits, penalties or judgments
              or
              administrative or judicial orders (including, without limitation,
              reasonable attorneys’ fees and expenses) incurred, assessed or sustained
              by or against DEXO, its Affiliates, directors, officers, employees
              or
              agents with respect to a claim by a Third Party arising out of (a)
              the
              negligent acts or omissions of ULURU; (b) any breach by ULURU of this
              Agreement or its representations, warranties or covenants hereunder;
              (c)
              any Recall or Seizure attributable to ULURU’s performance (including,
              without limitation, amounts DEXO pays or credits to its customers for
              Product so Recalled or Seized); (d) product liability, tort, nuisance
              or
              other claim arising out of the defective manufacture, storage or supply
              of
              the Product by ULURU; (e) any allegation that the manufacture,
              importation, sale, offer for sale or use of the Product infringes any
              patent or other intellectual property, proprietary or protected right
              within the Territory; provided that ULURU will not be obligated to
              indemnify DEXO if and to the extent that the alleged infringement is
              caused by: (i) DEXO’s (including, without limitation, its Affiliates,
              agents, contractors, and sub-distributors) or its customers misuse
              or
              modification of the Product; or (ii) DEXO’s (including, without
              limitation, its Affiliates, agents, contractors, and sub-distributors)
              or
              its customers use of the Product in combination with any products or
              materials not provided by ULURU; and further provided that if the Product
              is held to constitute an infringement or misappropriation of any Third
              Party’s intellectual property rights or if in ULURU’s opinion, the Product
              is, or is likely to be held to constitute, an infringement or
              misappropriation, ULURU may at its expense and option: (x) procure
              the
              right for DEXO to continue distributing the Product; (y) upon prior
              approval by DEXO, which approval will not be unreasonably withheld
              or
              delayed, promptly replace the Product with a non-infringing and
              non-misappropriating equivalent product conforming to the applicable
              Product Specifications and Regulatory Approvals; provided that there
              shall
              not be any material delay in any such replacement; or (z) upon prior
              approval by DEXO, which approval will not be unreasonably withheld
              or
              delayed, modify the Product to make it non-infringing and
              non-misappropriating while conforming to the applicable Product
              Specifications and Regulatory Approvals; provided that there shall
              not be
              any material delay in any such modification; (f) any enforcement or
              other
              action by any Regulatory Authority relating to the Manufacture, the
              pricing of the Product by ULURU to DEXO or sale of the Product by ULURU
              to
              DEXO; or (f) ULURU’s failure to comply with any applicable law, regulation
              or order (including, without limitation, environmental laws, regulations
              and orders). The foregoing indemnification obligation shall not apply
              in
              the event and to the extent that such claim arose as a result of any
              indemnitee’s negligence, intentional misconduct or breach of this
              Agreement. The provisions of this Section shall survive the termination
              or
              expiration of this Agreement.
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|7.1.2. | DEXO
              shall defend, indemnify and hold harmless ULURU, its directors, officers,
              employees and agents from and against all damages, losses, liabilities,
              expenses, claims, demands, suits, penalties or judgments or administrative
              or judicial orders (including, without limitation, reasonable attorneys’
              fees and expenses) incurred, assessed or sustained by or against ULURU,
              its directors, officers, employees or agents with respect to a claim
              by a
              Third Party arising out of (a) the negligent acts or omissions of DEXO;
              (b) any breach by DEXO of this Agreement or of its representations,
              warranties or covenants hereunder; (c) any allegation that the Trademarks
              or DEXO’s packaging or DEXO’s (or any Affiliate of DEXO’s) marketing
              materials infringes any patent or other proprietary or protected right
              of
              any Third Party; (d) any Recall or Seizure attributable to DEXO’s
              performance;
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




(e)
      any
      enforcement or other action by any Regulatory Authority relating to the
      distribution, the pricing of the Product by DEXO or sale of the Product by
      DEXO
      to Third Parties; (f) DEXO’s failure to comply with any applicable law,
      regulation or order (including, without limitation, environmental laws,
      regulations and orders), or (g) the marketing and distributing of the Product
      by
      DEXO, its Affiliates or sub-distributors. The foregoing indemnification
      obligation shall not apply in the event and to the extent that such claim arose
      as a result of any indemnitee’s negligence, intentional misconduct or breach of
      this Agreement. The provisions of this Section shall survive the termination
      or
      expiration of this Agreement.





|7.1.3. | To
              receive the benefit of indemnification under this Section 7.1, the Party
              and its Affiliates, directors, officers, employees or agents seeking
              indemnification (an “Indemnified Party”) shall promptly notify the other
              Party (the “Indemnifying Party”), in writing, of any claim asserted or
              threatened against such Indemnified Party for which such Indemnified
              Party
              is entitled to indemnification hereunder from the Indemnifying Party.
              With
              respect to any such claim the Indemnified Party shall, at no out-of-pocket
              expense to it, reasonably cooperate with and provide such reasonable
              assistance to such Indemnifying Party as such Indemnifying Party may
              reasonably request. Such reasonable assistance may include, without
              limitation, providing copies of all relevant correspondence and other
              materials that the Indemnifying Party may reasonably request. The
              obligations of an Indemnifying Party under Sections 7.1.1 and 7.1.2
              are
              conditioned upon the delivery of written notice to the Indemnifying
              Party
              of any asserted or threatened claim promptly after the Indemnified
              Party
              becomes aware of such claim; provided that the failure of the Indemnified
              Party to give such notice or any delay thereof shall not affect the
              Indemnified Party’s right to indemnification hereunder, except to the
              extent that such failure or delay impairs the Indemnifying Party’s ability
              to defend or contest any such claim. The Indemnifying Party shall have
              the
              right to assume the defense of any suit or claim for which indemnification
              is sought with counsel reasonably acceptable to the Indemnified Party.
              If
              the Indemnifying Party defends the suit or claim, the Indemnified Party
              may participate in the defense thereof at its sole cost and expense.
              An
              Indemnifying Party may not settle a suit or claim without the consent
              of
              the Indemnified Party if (a) such settlement would impose any monetary
              obligation on the Indemnified Party for which indemnification is not
              provided hereunder, (b) or require the Indemnified Party to submit
              to an
              injunction or otherwise limit the Indemnified Party’s rights under this
              Agreement, or (e) does not include a release of the Indemnified Party
              from
              all liability arising out of such suit or claim. Any payment made by
              an
              Indemnifying Party to settle any such suit or claim shall be at its
              own
              cost and expense.
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|7.1.4. | The
              indemnification provided by this Section 7 shall be the Parties’ sole and
              exclusive remedy in connection with any Third Party
              claim.
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|7.2. | Insurance.
|---- | ----------




At
      the
      time of Launch and continuing through the Term of this Agreement, ULURU shall
      maintain the following kinds of insurance with the minimum limits set forth
      below.





Kind
                of Insurance
            Minimum
                LimitsCommercial
                General Liability, including Contractual, Completed Operations and
                Product
                Liability
            $2,000,000
                Per OccurrenceWorkers
                Compensation
            $5,000,000
                Aggregate Statutory with Employer’s Liability of not less than $1,000,000
                Per Accident/DiseaseAutomobile
                Bodily Injury Liability (including hired automobile and non-ownership
                Liability)
            $1,000,000
                Each Accident Combined Single
                Limit.





Upon
      request, ULURU shall furnish insurance certificates as directed by DEXO,
      satisfactory in form and substance to DEXO, showing the above coverages, and
      providing for at least thirty (30) days’ prior written notice to DEXO by the
      insurance company of cancellation or modification. DEXO shall be named as an
      additional insured on the ULURU’s policies. Coverage shall be procured with
      carriers having an A.M. Best rating of A-Vu or better.





|8. | TERM
              AND TERMINATIONS.
|-- | ------------------------------------




|8.1. | Term.
|---- | -----




This
      Agreement shall commence on the date of first sale of the Product in the
      Territory and shall continue in hill force for a period often (10) years.
      Thereafter, the Agreement shall be automatically extended for subsequent
      two-year (2) periods unless terminated by either party in writing giving at
      least one hundred (180) days prior notice to the end of the initial term or
      any
      extension thereof.





|8.2. | Termination
              Without Cause.
|---- | ----------------------------------------




DEXO
      may
      terminate this Agreement at any time (a) after Launch by giving twelve (12)
      months prior written notice to ULURU if DEXO, in its sole discretion, determines
      to cease marketing the Product, or (b) prior to Launch by giving thirty (30)
      days prior written notice to ULURU if DEXO, in its sole discretion, determines
      not to Launch the Product. If DEXO decides not to launch the Product in any
      specific country in the Territory, the commercial rights shall revert to ULURU.
      If DEXO terminates this Agreement pursuant to subsection (a) above, DEXO is
      not
      obligated to transfer to ULURU any data relating to the Product (including,
      without limitation, marketing studies or otherwise) that DEXO generated prior
      to
      such termination. If DEXO terminates this Agreement pursuant to subsection
      (b)
      above, then, subject to the exceptions set forth in Section 8.3, DEXO shall
      transfer to ULURU any data relating solely to the Product that DEXO
      generated.





|8.3. | Termination
              for Regulatory Action or Claim of
              Infringement.
|---- | ---------------------------------------------------------------------------------------




DEXO
      may
      terminate this Agreement in its entirety immediately if the FDA or any other
      Regulatory Authority takes any action, the result of which is to prohibit or
      permanently or otherwise restrict the Manufacture, storage, importation, sale,
      offer for sale or use of the Product in any way that will have a material,
      adverse effect on the sale price or sales volumes of the Product, or if any
      claim is made that the Manufacture, storage, importation, sale, offer for sale
      or use of the Product infringes any patent or other proprietary or protected
      right of any Third Party.





|8.4. | Termination
              for Breach.
|---- | -------------------------------------




If
      either
      Party shall at any time fail to discharge any of its obligations hereunder
      and
      shall fail to correct such default within thirty (30) days after the other
      Party
      shall have given written notice to it thereof, the aggrieved Party shall be
      entitled to notify the other Party that it intends to terminate this Agreement
      unless such default is corrected and may so terminate ten (10) days after the
      end of such thirty (30) day period if such default is continuing; provided
      that
      if such default by the other Party shall be a recurring default and the other
      Party does not reasonably satisfy the aggrieved party that such defaults shall
      cease to occur, the aggrieved Party shall be entitled to terminate this
      Agreement upon the occurrence of such default and the other Party shall not
      be
      entitled to correct such default.





|8.5. | Termination
              for Bankruptcy.
|---- | -----------------------------------------




If
      either
      Party by voluntary or involuntary action goes into liquidation, dissolves or
      files a petition for bankruptcy or suspension of payments, is adjudicated
      bankrupt, has a receiver or trustee appointed for its property or estate,
      becomes insolvent or makes an assignment for the benefit of creditors, the
      other
      Party shall be entitled by notice in writing to such Party to terminate this
      Agreement forthwith.





|8.6. | Effect
              of Termination.
|---- | ------------------------------------




Termination
      or expiration of this Agreement, in whole or in part, shall be without prejudice
      to the right of either Party to receive all payments accrued and unpaid at
      the
      effective date of such termination or expiration, without prejudice to the
      remedy of either Party in respect to any previous breach of any of the
      representations, warranties or covenants herein contained and without prejudice
      to any other provisions hereof which expressly or necessarily call for
      performance after such termination or expiration.





|8.7. | DEXO’s
              Rights on Termination.
|---- | -------------------------------------------




Upon
      termination or expiration of this Agreement for any reason, then (a) at DEXO’s
      request, ULURU shall supply DEXO with its inventory of Materials, Product and/or
      works-in-progress for the Manufacture, packaging and labeling of Product and
      DEXO shall pay ULURU the manufacturing fee for the Product, a prorated portion
      thereof for work-in-progress commenced against firm orders by DEXO and the
      cost
      of Materials.





|8.8. | Survival.
|---- | ---------




The
      following provisions shall survive the expiration or termination of this
      Agreement:


Sections
      3.4, 3.6, 3.7, 5.5, 5.6, 5.7, 5.8, 5.9, 5.10, 7.1, 8.6, 8.7 and 8.8, and
      Articles 9, 11, 12 and 13.





|9. | CONFIDENTIALITY
|-- | ---------------




|9.1. | Nondisclosure
              Obligation.
|---- | ---------------------------------------




Each
      of
      ULURU and DEXO shall use only in accordance with this Agreement and shall not
      disclose to any Third Party the Confidential Information received by it from
      the
      other Party pursuant to this Agreement, without the prior written consent of
      the
      other Party. The foregoing obligations shall survive for a period of five (5)
      years after the termination or expiration of this Agreement. These obligations
      shall not apply to Confidential Information that: (a) is known by the receiving
      Party at the time of its receipt, and not through a prior disclosure by the
      disclosing Party, as documented by business records; (b) is at the time of
      disclosure or thereafter becomes published or otherwise part of the public
      domain without breach of this Agreement by the receiving Party; (c) is
      subsequently disclosed to the receiving Party by a Third Party who has the
      right
      to make such disclosure; (d) is developed by the receiving Party independently
      of the Confidential Information received from the disclosing Party and such
      independent development can be documented by the receiving Party; or (e) is
      required by law, regulation, rule, act or order of any governmental authority
      or
      agency to be disclosed by a Party, provided that notice is promptly delivered
      to
      the other Party in order to provide an opportunity to seek a protective order
      or
      other similar order with respect to such Confidential Information and thereafter
      the disclosing Party discloses to the requesting entity only the minimum
      Confidential Information required to be disclosed in order to comply with the
      request, whether or not a protective order or other similar order is obtained
      by
      the other Party.





|9.2. | Permitted
              Disclosures.
|---- | ------------------------------------




Each
      Party may disclose the other Party’s Confidential Information to its employees
      and Affiliates on a need-to-know basis and to its agents or consultants to
      the
      extent required to accomplish the purposes of this Agreement; provided that
      the
      recipient Party obtains prior agreement from such agents and consultants to
      whom
      disclosure is to be made to hold in confidence and not make use of such
      Confidential Information for any purpose other than those permitted by this
      Agreement. Each Party will use at least the same standard of care as it uses
      to
      protect proprietary or confidential information of its own to ensure that such
      employees, agents, consultants, and Affiliates do not disclose or make any
      unauthorized use of the other Party’s Confidential Information.





|9.3. | Disclosure
              of Agreement.
|---- | --------------------------------------




Neither
      ULURU nor DEXO shall release to any Third Party or publish in any way any
      non-public information with respect to the terms of this Agreement without
      the
      prior written consent of the other Party, which consent shall not be
      unreasonably withheld or delayed, provided that either Party may disclose the
      terms of this Agreement (a) to the extent required to comply with applicable
      laws, including, without limitation, the rules and regulations promulgated
      by
      the United States Securities and Exchange Commission; provided, further, that
      prior to making any such disclosure, the Party intending to so disclose the
      terms of this Agreement shall (i) provide the nondisclosing Party with written
      notice of the proposed disclosure and an opportunity to review and comment
      on
      the intended disclosure which is reasonable under the circumstances and (ii)
      shall seek confidential treatment for as much of the disclosure as is reasonable
      under the circumstances, including, without limitation, seeking confidential
      treatment of any information as may be requested by the other Party; or (b)
      to
      one or more Third Parties and/or their advisors in connection with a proposed
      spin-off, joint venture, divestiture, merger or other similar transaction
      involving all, or substantially all, of the Product, assets or business of
      the
      disclosing Party to which this Agreement relates or to lenders, investment
      bankers and other financial institutions of its choice solely for purposes
      of
      financing the business operations of such Party; provided, further, that either
      (i) the other Party has consented to such disclosure or (ii) such Third Parties
      have signed confidentiality agreements with respect to such information on
      terms
      no less restrictive than those contained in this Article 9; or (c) to its legal
      counsel.





|9.4. | Publicity.
|---- | ----------




All
      publicity, press releases and other announcements relating to this Agreement
      or
      the transactions contemplated hereby shall be reviewed in advance by, and shall
      be subject to the approval of, both Parties.





|10. | FORCE
              MAJEURE
|--- | ---------------------------




If
      the
      Manufacture, production, delivery, acceptance or use of Product specified for
      delivery under this Agreement or if the performance of any other obligation
      hereunder is prevented, restricted or interfered with by reason of fires,
      accidents, explosions, earthquakes, floods, breakdown of plant, embargoes,
      government ordinances or requirements, civil or military authorities, acts
      of
      God or of the public enemy, or other similar causes beyond the reasonable
      control of the Party whose performance is affected (any of the foregoing a
      “Force Majeure Event”), then the Party affected, upon giving prompt written
      notice to the other Party, shall be excused from such performance on a
      day-for-day basis to the extent of such prevention, restriction, or interference
      (and the other Party shall likewise be excused from performance of its
      obligations on a day-for-day basis to the extent such Party’s obligations relate
      to the performance so prevented, restricted or interfered with); provided that
      the Party so affected shall use commercially reasonable efforts to avoid or
      remove such causes of non-performance and both Parties shall proceed to perform
      their obligations with dispatch whenever such causes are removed or cease.
      If
      such Force Majeure Event continues for a period of ninety (90) consecutive
      days
      or more and as a result either party has been unable to perform its obligations
      under this Agreement for such ninety (90) day period, the other Party may
      terminate this Agreement effective immediately, upon delivery of a notice of
      termination in writing, provided that such event of Force Majeure Event is
      continuing. If as a result of any Force Majeure Event above, ULURU is unable
      to
      fully supply DEXO’s orders hereunder, ULURU shall allocate all available
      quantities of Materials and Product to DEXO in the ratio that the quantities
      ordered by DEXO in the twelve (12) month period immediately preceding such
      force
      majeure event bears to ULURU’s requirements for its own use and for supply to
      Third Parties for that same period; provided that if this Agreement has not
      been
      in effect for a full twelve (12) month period, then such shorter period shall
      be
      used in lieu of a twelve (12) month period.





|11. | INTELLECTUAL
              PROPERTY
|--- | -----------------------------------




|11.1. | Trademarks:
              DEXO Intellectual Property.
|----- | -----------------------------------------------------




|11.1.1. | DEXO
              may advertise, promote, market and sell the Product either separately
              or
              as part of other products under any of its Trademarks and/or trade
              dress,
              whether registered or unregistered, in its sole discretion; provided
              that
              except as otherwise expressly permitted under Section 2.1.4 with respect
              to the Mark, DEXO may not use or adopt any ULURU Trademark or trade
              dress,
              or any such item confusingly similar thereto used or intended to be
              used
              prior to the first use of such Trademark. ULURU shall have no right,
              title
              or interest in or to any such DEXO Trademark or trade dress, and DEXO
              shall have no right, title or interest in or to any such ULURU Trademark
              (except for the license to the Mark granted under Section 2.1.4). So
              long
              as DEXO or any Affiliate of DEXO shall have any interest in any such
              Trademark or trade dress, whether registered or unregistered, whether
              as
              proprietor, owner, or licensee in any country of the world, ULURU shall
              not adopt, use, apply for registration, register or own such Trademark
              or
              trade dress, or any such item confusingly similar thereto in any country
              of the world, or take any action which weakens or undermines DEXO’s
              proprietary rights therein. So long as ULURU or any Affiliate of ULURU
              shall have any interest in any such ULURU Trademark or trade dress,
              whether registered or unregistered, whether as proprietor, owner, or
              licensee in any country of the world, except as otherwise expressly
              permitted under Section 2.1.4 with respect to the Mark, DEXO shall
              not
              adopt, use, apply for registration, register or own such ULURU Trademark
              or trade dress, or any such item confusingly similar thereto in any
              country of the world, or take any action which weakens or undermines
              ULURU’s proprietary rights therein.
|------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.1.2. | For
              the avoidance of doubt, DEXO shall at all times retain sole and exclusive
              ownership of its intellectual property, including, without limitation,
              all
              marketing and sales plans, artwork, formats, equipment, logos, drawings,
              customer lists, regulatory filings, correspondence with the FDA or
              any
              other Regulatory Authority, clinical study data, analytical data,
              operating procedures and all ordering and sales
              information.
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.2. | Inventions.
|----- | -----------




|11.2.1. | Except
              as otherwise provided for in this Section 11.2, each Party shall own
              all
              Inventions made solely by employees of such Party (or Third Parties
              acting
              on behalf of such Party) and shall jointly own with the other Party
              any
              Invention made jointly by employees of both Parties (or Third Parties
              on
              behalf of one or both Parties); provided that such Inventions were
              made
              without violation of any term or condition of this Agreement. All
              determinations of inventorship under this Agreement shall be made in
              accordance with United States law.
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.2.2. | If
              and to the extent applicable, Inventions Controlled by ULURU and know-how
              arising during the Term which specifically relates to the Product and
              is
              Controlled by ULURU shall be automatically included in the Intellectual
              Property Rights under which DEXO is Licensed pursuant to Section 2.1.1
              hereof. With respect to any Inventions or know-how Controlled by DEXO
              specifically relating to the Product, DEXO hereby grants to ULURU an
              exclusive (subject to retained rights in DEXO), royalty-free license
              to
              use such Invention for the Manufacture of the Product for DEXO in the
              Territory during the Term.
|------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.2.3. | During
              the Term of this Agreement both Parties shall require their employees
              and
              personnel involved in the performance of its duties under this Agreement
              to deliver such assignments, confirmations of assignments or other
              written
              instruments as are necessary to vest in the respective Party clear
              and
              marketable title to the Inventions.
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.2.4. | All
              rights, title and interest in and to the ULURU Intellectual Property
              Rights shall remain exclusively owned by ULURU. The Inventions owned
              by
              ULURU under this Section shall be referred to herein as “ULURU
              Inventions”.
|------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.2.5. | All
              rights, title, and interest in and to know-how, which is developed
              jointly
              by the Parties during the Term of this Agreement and related to the
              Product, its Manufacture and/or use shall be owned jointly by the Parties.
              All rights, title, and interest in and to any Regulatory Approval the
              primary responsibility for which is allocated to a particular Party
              hereunder that is developed or collected solely or jointly by the Parties
              in the Territory during the Term of this Agreement shall be owned
              exclusively by such Party.
|------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.3. | Confidentiality
              of Information related to Intellectual
              Property.
|----- | --------------------------------------------------------------------------------------------




Any
      and
      all information and material, including, without limitation, any and all
      intellectual property rights therein and thereto, assigned to a Party pursuant
      to the terms of this Agreement shall constitute Confidential Information of
      such
      Party which shall be deemed the Disclosing Party with respect to such
      Confidential Information.





|11.4. | Patent
              Rights to New inventions.
|----- | ----------------------------------------------




|11.4.1. | ULURU,
              at its own expense, shall use commercially reasonable efforts to prepare,
              file, prosecute and maintain its Intellectual Property Rights in the
              countries of the Territory.
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.4.2. | With
              respect to any filings after the Effective Date, ULURU shall give DEXO
              a
              reasonable opportunity to review and comment upon the text of such
              applications in the Territory before filing, shall consult in good
              faith
              with DEXO with respect to such applications in the Territory, and shall
              supply DEXO with a copy of such applications in the Territory as filed,
              together with notice of its filing date and serial number. ULURU shall
              inform DEXO about the status of the prosecution of all patent applications
              included within the ULURU Intellectual Property Rights and its
              Intellectual Property Rights to Inventions and the maintenance of any
              patents included within the ULURU Intellectual Property Rights and
              its
              Intellectual Property Rights to Inventions in a country in the
              Territory.
|------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.4.3. | ULURU
              shall consult with DEXO and provide DEXO with reasonable opportunity
              to
              comment on all correspondence received from and all submissions to
              be made
              to any Regulatory Authority in the Territory with respect to any such
              patent application or patent. ULURU shall consider in good faith, but
              will
              not be bound by, DEXO’s suggestions with respect to all submissions in the
              Territory made to any Regulatory Authority in the Territory with respect
              to any such patent application or patent.
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.4.4. | If
              ULURU elects not to file a patent application with respect to its new
              Inventions or to cease the prosecution and/or maintenance of any Patent
              under the ULURU Intellectual Property Rights in a country in the
              Territory, ULURU shall provide DEXO with written notice promptly after
              the
              decision to not file or continue the prosecution of such patent
              application or maintenance of such
              patent.
|------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.4.5. | In
              such event, ULURU shall permit DEXO, in DEXO’s sole discretion, to file a
              patent application with respect to such Invention or continue prosecution
              or maintenance of any such Patent under the ULURU Intellectual Property
              Right in such country at DEXO’s own expense. If DEXO elects to continue
              such prosecution or maintenance, ULURU shall execute such documents
              and
              perform such acts, at DEXO’s expense, as may be reasonably necessary to
              permit DEXO to file, prosecute or maintain such application or Patent
              in
              such country. In such event, DEXO shall own such patent application
              or
              Patent filed by DEXO hereunder.
|------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.4.6. | In
              the event that DEXO continues the prosecution or maintenance of such
              patent application or Patent pursuant to this Section, DEXO’s Royalty
              obligations hereunder, and this Agreement, shall expire if, and at
              such
              time, that such patent application or Patent becomes the only non-expired
              Patent rights within the Intellectual Property
              Rights.
|------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.4.7. | (a)
              The Parties shall mutually agree in good faith on a case-by-case-basis
              on
              which of the Parties shall have the first right to prepare, file,
              prosecute and maintain any jointly owned Invention and patent rights
              thereon (“Joint Patent Rights”) throughout the world as well as on the
              split of the applicable expenses and
              costs.
|------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




(b)
      The
      acting Party shall keep the other Party completely informed during the whole
      application procedure as well as during the whole patent duration. The acting
      Party shall provide the other Party advance copies of any official
      correspondence related to the filing, prosecution and maintenance of such patent
      filings, and shall provide the other Party a reasonable opportunity to comment
      on all correspondence received from and all submission to be made to any
      government patent office or authority with respect to any such patent
      application or patent, and shall consider in good faith the other Party’s
      suggestions with respect to all submission made to any government office or
      authority.





(c)
      If
      either Party (the “Declining Party”) at any time declines to share in the costs
      of filing, prosecuting and maintaining any such Joint Patent Right, on a country
      by country basis, the Declining Party shall provide the other Party (the
“Continuing Party”) with thirty (30) days prior written notice to such effect,
      in which event, the Declining Party shall (i) have no responsibility for any
      expenses incurred in connection with such Joint Patent Right and (ii) if the
      Continuing Party elects to continue prosecution or maintenance, the Declining
      Party, upon the Continuing Party’s request, shall execute such documents and
      perform such acts, at the Continuing Party’s expense, as may be reasonably
      necessary (x) to assign to the Continuing Party all of the Declining Party’s
      right, title and interest in and to such Joint Patent Rights and (y) to permit
      the Continuing Party to file, prosecute and/or maintain such Joint Patent
      Right.





(d)
      If
      DEXO is (i) the sole owner of a Joint Patent Right or (ii) the Continuing Party,
      such Joint Patent Right shall no longer be considered to be part of the ULURU
      Intellectual Property Rights for purposes of this Agreement and thereafter
      shall
      be part of DEXO’ s intellectual property.





(e)
      If
      ULURU is (i) the sole owner of a Joint Patent Right or (ii) is the Continuing
      Party, such Joint Patent Rights shall no longer be considered to be part of
      DEXO’s intellectual property for purposes of this Agreement and thereafter shall
      be part of the ULURU Intellectual Property Rights.





|11.4.8. | Each
              Party shall, and shall cause its Affiliates, employees, attorneys and
              agents to, cooperate fully with the other Party and provide all
              information and data and execute any documents reasonably required
              or
              requested in order to allow the other Party to prosecute, file, and
              maintain patents and patent applications pursuant to this Section 11.4.
              Neither Party shall require the other Party to make any payment or
              reimburse for any expenses in connection with such cooperation, provision
              of information and data and execution of
              documents.
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.5. | Enforcement
              of Intellectual Property Rights.
|----- | ----------------------------------------------------------




|11.5.1. | If
              either Party becomes aware of any infringement of any of the Intellectual
              Property Rights or the Mark, or the validity of any of the Intellectual
              Property Rights or the Mark is challenged by a Third Party in the
              Territory, such Party will notify the other Party in writing to that
              effect. Any such notice shall include, as applicable, evidence to support
              an allegation of infringement by such Third
              Party.
|------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.5.2. | ULURU
              shall have the first right, but not the obligation, to take action
              to
              obtain a discontinuance of infringement or bring suit against a Third
              Party infringer of Intellectual Property Rights and/or the Mark in
              the
              Territory. Such right shall remain in effect until ninety (90) days
              after
              the date of notice given under Section 11.5.1. In the event that ULURU
              exercises such right, then: (a) ULURU shall not consent to the entry
              of
              any judgment or enter into any settlement with respect to such an action
              or suit without the prior written consent of DEXO (not to be unreasonably
              withheld), and (b) ULURU shall bear all the expenses of any such suit
              brought by ULURU claiming infringement of any Intellectual Property
              Rights
              and/or the Mark. If, after the expiration of the ninety (90) day period,
              ULURU has not obtained, or is not diligently pursuing, a discontinuance
              of
              infringement of the Intellectual Property Rights and/or the Mark, filed
              suit against any such Third Party infringer of the Intellectual Property
              Rights and/or the Mark, or provided DEXO with information and arguments
              demonstrating to DEXO’s reasonable satisfaction that there is insufficient
              basis for the allegation of such infringement of the Intellectual Property
              Rights and/or the Mark, then DEXO shall have the right, but not the
              obligation, to bring suit against such Third Party infringer of the
              Intellectual Property Rights and/or the Mark and to join ULURU as a party
              plaintiff, provided that DEXO shall bear all the expenses of such suit.
              In
              such event, DEXO shall not consent to the entry of any judgment or
              enter
              into any settlement with respect to such an action or suit without
              the
              prior written consent of ULURU (which consent shall not unreasonably
              be
              withheld) if such judgment or settlement includes a finding or agreement
              that such Intellectual Property Right and/or the Mark is invalid or
              would
              enjoin or grant other equitable relief against
              ULURU.
|------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.5.3. | Each
              Party shall cooperate (including, without limitation, by executing
              any
              documents reasonably required to enable the other Party to initiate
              such
              litigation, testifying when requested or providing relevant documents)
              with the other Party in any suit for infringement of Intellectual Property
              Rights and/or the Mark brought by the other Party against a Third Party
              in
              accordance with this Section and shall have the right to consult with
              the
              other Party and to participate in and be represented by independent
              counsel in such litigation at its own
              expense.
|------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.5.4. | Neither
              Party shall be required pursuant to this Section 11.5 to undertake
              any
              activities, including, without limitation, legal discovery at the request
              of a Third Party except as may be required by lawful process of a court
              of
              competent jurisdiction.
|------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.5.5. | Neither
              Party shall incur any liability to the other Party as a consequence
              of any
              such litigation or any unfavorable decision resulting there from,
              including, without limitation, any decision holding any of the patents
              within the Intellectual Property Rights invalid or
              unenforceable.
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.5.6. | Any
              recovery obtained by either Party as a result of any such proceeding
              against a Third Party infringer shall be allocated as follows: (a)
              such
              recovery shall first be used to reimburse each Party for all litigation
              costs in connection with such litigation paid by that Party; and (b)
              the
              Party bringing the action shall receive the remaining portion of such
              recovery after payment of the amounts specified in clause
              (a).
|------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.6. | Trademarks.
|----- | -----------




Subject
      to the restrictions in Sections 2.1.4 and 11.1, DEXO shall select and own all
      Trademarks in connection with the marketing, promotion and sale of the Product
      in the Territory other than the ULURU Trademarks. DEXO hereby grants to ULURU
      a
      limited, non-exclusive, non-transferable, fully paid, royalty free,
      sublicensable license in and to all DEXO Trademarks and copyrights to be
      contained in any such labeling for the sole purpose of manufacturing and
      applying such labels to the Product in the conduct of ULURU’s obligations
      hereunder; provided, however, that ULURU agrees to cooperate with and offer
      reasonable assistance to DEXO in facilitating DEXO’s control of the quality of
      the Product branded with DEXO’s trademarks hereunder; but further provided that
      in no event is ULURU obligated to provide such cooperation or assistance in
      any
      way that will (i) lower the quality of the Product below that which ULURU deems
      acceptable for general commercial distribution, (ii) be contrary to or in
      violation of any regulatory or statutory obligations, or (iii) increase the
      cost
      of manufacturing and delivering the Product hereunder beyond that contemplated
      by the parties as of the Effective Date.





|11.7. | Publications.
|----- | -------------




|11.7.1. | The
              Parties recognize that limited rights of review and/or comment exist
              for
              certain Third Party publications, such as medical, academic and scientific
              publications. Each Party agrees to provide the other Party with any
              such
              proposed publication or presentation with respect to the Product promptly
              upon its receipt. Each Party may advise the other of any comments that
              it
              may have relating to such proposed publication or presentation and
              do so
              within the applicable time frame.
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.7.2. | During
              the Term of this Agreement, unless otherwise prohibited by law, each
              Party
              shall submit to the other Party for review and approval any proposed
              publication or public presentation, especially including, without
              limitation, academic, scientific and medical information, which contains
              the non-disclosing Party’s Confidential Information or which disclose any
              non-public information contained within the Intellectual Property Rights
              or which makes any reference to the subject matter of this Agreement
              or
              the Product.
|------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.7.3. | Written
              copies of each such proposed publication or presentation required to
              be
              submitted hereunder shall be submitted to the non-disclosing Party
              no
              later than fifteen (15) days before its intended submission for
              publication or presentation. The nondisclosing Party shall provide
              its
              comments with respect to such publications and presentations within
              ten
              (10) business days of its receipt of such written copy. The review
              period
              may be extended for an additional thirty (30) days in the event the
              non-disclosing Party can demonstrate reasonable need for such extension.
              By mutual agreement of the Parties in writing, this period may be further
              extended.
|------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.7.4. | The
              Parties acknowledge that as publicly held corporations, the Parties
              may
              not lawfully disclose in advance certain information to any party,
              including, without limitation, the other Party. This may affect the
              Parties’ ability to submit for review certain proposed publications and
              public presentations.
|------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|11.7.5. | Regarding
              their publications under this Section 11.7, ULURU and DEXO will each
              comply with standard academic practice regarding authorship of scientific
              publications and recognition of contribution of other parties in any
              publication.
|------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|12. | NOTICES
|--- | -------




|12.1. | Ordinary
              Notices.
|----- | -------------------------------

Correspondence,
      reports, documentation, and any other communication in writing between the
      Parties in the course of ordinary implementation of this Agreement shall be
      delivered by hand, sent by facsimile or by overnight courier to the employee
      or
      representative of the other Party who is designated by such other Party to
      receive such written communication at the address or facsimile numbers specified
      by such employee or representative.





|12.2. | Extraordinary
              Notices.
|----- | ------------------------------------




|12.2.1. | Extraordinary
              notices and communications (including, without limitation, notices
              of
              termination, Force Majeure Event, material breach, change of address,
              requests for disclosure of Confidential Information, claims or
              indemnification) shall be in writing and shall be delivered by hand,
              sent
              by facsimile or by overnight courier (and shall be deemed to have been
              properly served to the addressee upon receipt of such written
              communication) to the address set forth in Section 12.3 or such other
              address as notified in writing by such Party to the other
              Party.
|------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|12.3. | Addresses.
|----- | ----------




If
      to
      DEXO:





DEXO  BioPharm
      Ltd.


Capital
      Tower


91
      Waterloo Road


London,
      SE1 8RT


Attention:
      Chief Executive Officer


Facsimile
      No.: 011-44-207-098-9883


Copy
      to:
      Company Secretary





If
      to
      ULURU:





ULURU
      Inc.


4452
      Beltway Drive


Addison,
      TX 75001


Attention:
      President & CEO


Facsimile
      No.: 214-905-5145





With
      a
      copy to:





John
      J.
      Concannon, Esq.


Bingham
      McCutchen LLLP


150
      Federal Street


Boston,
      MA 02110


Facsimile
      No.: 617-951-8736





|13. | GENERAL
|--- | -------




|13.1. | Governing
              Law.
|----- | ----------------------------




This
      Agreement shall be construed in accordance with and governed by the law of
      the
      State of New York, without giving effect to its conflict of laws provisions,
      and
      to the exclusion of the provisions of the United Nations Convention on Contracts
      for the International Sale of Goods.





|13.2. | Equal
              Opportunity Clause.
|----- | ---------------------------------------




The
      Equal
      Opportunity Clause required by Executive Orders 11246, as amended (41-CFR
      60-1.4) and 11375, the Employment Assistance to Veterans Clause required by
      Executive Order 11701(41 CFR 60-250.4), the Vietnam Era Veteran Readjustment
      Act
      of 1972, the Employment of the Handicapped Clause required by the Rehabilitation
      Act of 1973 (41 CFR 60-74 1.4) and the Americans with Disabilities Act of 1991
      are part of this Agreement and binding upon ULIURU unless exempted by rules,
      regulations or orders of the Secretary of Labor. ULURU agrees that the
      applicable clause with regard to the utilization of minority contractors set
      forth at 41 CFR 1-1.303 and the applicable clause with regard to the Utilization
      of Small Business Concerns and Small Business Concerns Owned and Controlled
      by
      Socially and Economically Disadvantaged Individuals set forth at 41 CFR 1-1.13
      are incorporated herein by reference, as applicable. ULURU agrees to provide
      information and documentation with respect to the foregoing to DEXO upon
      request.





|13.3. | Assignment.
|----- | -----------




This
      Agreement shall not be assignable or transferable by either Party without the
      prior written consent of the other Party(which consent shall not be unreasonably
      withheld); provided that either Party may assign this Agreement and its rights
      and obligations hereunder without the other Party’s consent in connection with
      the transfer or sale of all or substantially all of the business of such party
      to which this Agreement relates (or, if applicable, the business unit or
      division of such Party primarily responsible for performance under this
      Agreement) to another party, whether by merger, sale of stock, sale of assets
      or
      otherwise. In the event that DEXO sublicenses the Agreement or any rights or
      obligations hereunder in accordance with the previous sentence, then DEXO shall
      guaranty the performance of the sublicensee. In the event that either DEXO
      or
      ULURU assigns this Agreement in accordance with this Section 13.3, then the
      assigning Party shall be released from its obligations hereunder and shall
      have
      no further obligations to the other Party pursuant to this Agreement. The rights
      and obligations of the parties under this Agreement shall be binding upon and
      inure to the benefit of the successors and permitted assigns of the parties.
      Any
      attempted assignment in violation of this Section 13.3 shall be null and void,
      without any force or effect.





|13.4. | Entire
              Agreement.
|----- | -------------------------------




This
      Agreement and all Exhibits attached hereto (as the same may be amended from
      time
      to time by the written agreement of the Parties) constitute the entire agreement
      between the Parties with respect to the subject matter hereof and supersedes
      all
      other documents, agreements, verbal consents, arrangements and understandings
      between the Parties with respect to the subject matter hereof. This Agreement
      shall not be amended orally, but only by an agreement in writing, signed by
      both
      Parties that states that it is an amendment to this Agreement.





|13.5. | Severability.
|----- | -------------




If
      any
      term of this Agreement shall be found to be invalid, illegal or unenforceable,
      it is the intention of the parties that the remainder of this Agreement shall
      not be affected thereby; provided that neither Party’s rights under this
      Agreement are materially adversely affected. It is further the intention of
      the
      parties that in lieu of each such provision which is invalid, illegal or
      unenforceable, there be substituted or added as part of this Agreement a
      provision which shall be as similar as possible in the economic and business
      objectives intended by the Parties to such invalid, illegal or unenforceable
      provision, but which shall be valid, legal and enforceable. In the event that
      either Party’s rights are materially adversely affected as a result of a change
      in this Agreement as contemplated by this Section, such Party may terminate
      this
      Agreement by notice in writing to the other Party given no later than sixty
      (60)
      days after such change.





|13.6. | Independent
              Contractor.
|----- | -------------------------------------




Each
      Party shall act as an independent contractor and neither Party shall have any
      authority to represent or bind the other Party in any way.





|13.7. | No
              Waiver.
|----- | ------------------------




Any
      waiver by one Party of any right of such Party or obligation of the other Party
      must be in writing and shall not operate as a waiver of any subsequent right
      or
      obligation.





|13.8. | Counterparts.
|----- | -------------




This
      Agreement may be executed in two or more counterparts (including, without
      limitation, by facsimile transmission), each of which when so executed and
      delivered shall be an original, but all of which together shall constitute
      one
      and the same instrument.





DEXO
                BIOPHARM LTDBy:
            /s/
                Steve Martin
              Name:
                Steve Martin
              Title:
                Chief Development OfficerULURU,
                INC.By:
            /s/
                Kerry P. Gray
              Name:
                Kerry P. Gray
              Title:
                President & CEO







EXHIBIT
      A






**Product**






Erodible
      oral mucoadhesive disc (OraDisc B) containing 15mg of benzocaine packaged in
      blister packs of 8 and/or 16 (2x8) benzocaine erodible discs in an outer carton
      for the treatment of oral pain.










EXHIBIT
      B





**Quality
      Agreement**





Will
      be
      incorporated into a Manufacturing and Control Agreement to be agreed between
      the
      Parties.








EXHIBIT
      C





**Procedures
      for Reporting Adverse Events**





Promptly
      following the Effective Date of this Agreement the Parties shall agree upon
      the
      appropriate procedures for dealing with adverse event reporting. Product
      complaints and recalls consistent with the applicable regulatory requirements
      in
      the countries in which the Product are sold will be agreed between the
      Parties.





DEXO
      shall keep records of its distributors and sales of the Product undertaken
      by it
      to enable appropriate procedures to be implemented in the event that a voluntary
      or mandatory recall of any Product is required.





EXHIBIT
      D





**Price**





Through
      its Contract Manufacturer ULURU will supply DEXO with bulk blister packs of
      8
      Benzocaine discs (OraDisc B) and/or 16 (2x8) packaged in an outer carton. If
      DEXO requires a certain pack which is different from the above, this will be
      identified at least six (6) months prior to launch. The supply price (ex works)
      for these two packs will be:





|– | blister
              packs of 2x8 erodible oral benzocaine discs$1.50
|- | ----------------------------------------------------------------------

|– | blister
              packs of 8 erodible oral benzocaine discs$0.76
|- | --------------------------------------------------------------------




Batch
      sizes for the supply to DEXO will be agreed in the manufacturing
      agreement.





EXHIBIT
      E





**License
      Payments**





In
      consideration of the license and the rights granted, DEXO will make the
      following license payments to ULURU in US Dollars:





On
                signature of Supply & License Agreement $600,000 (non-refundable), the
                amount of to be paid in BIOPROGRESS PLC. company stock that can be
                immediately placed onto the open stock market*.
            $600,000One
                (1) year after signing the Agreement or upon The first submission
                of the
                agreed registration dossier with any of the countries within the
                TERRITORY, whichever is the later event, the amount of $600,000 to
                be paid
                in BIOPROGRESS PLC. company stock that can be immediately placed
                Immediately onto the open stock market*
            $600,000Upon
                Regulatory and price reimbursement approval, If applicable, whichever
                event is the later of OraDiscTM B prorated for the following
                markets:
            $500,000





|– | Germany
              20% ($100,000)
|- | ------------------------------------

|– | France
              20% ($100,000)
|- | -----------------------------------

|– | UK
              20% ($100,000)
|- | -------------------------------

|– | Italy
              20% ($100,000)
|- | ----------------------------------

|– | Spain
              20%($ 100,000)
|- | ----------------------------------




Cumulative
                net sales in the Territory equivalent to $US5 million for OraDiscTM
                B:
            
            $250,000Cumulative
                net sales in the Territory equivalent to $US10 million for OraDiscTM
                B:
            
            $250,000Cumulative
                net sales in the Territory equivalent to $US25 million for OraDiscTM
                B:
            
            $500,000





*BioProgress
      and DEXO shall guarantee that the net amount received by Uluru with respect
      to
      the sale of the shares shall be $600,000 U.S. Such amount shall not be reduced
      by (a) any fluctuation in the share price prior to sale, (b) any brokerage
      or
      other commissions paid in connection with the sale or (c) any other
      charge.








EXHIBIT
      F





**Minimum
      Sales**





DEXO
      agrees to annually sell the following percentages of the Volume Sales Forecast
      provided in the Territory (“Minimum Sales”) for the Product:





**Year
      1 25% of forecast**


**Year
      2 30% of forecast**


**Year
      3 35% of forecast**


**Year
      4 40% of forecast**


**Year
      5 50% of forecast**





If
      DEXO
      fails to achieve the annual Minimum Sales in the Territory, DEXO will have
      the
      option to either pay ULURU the shortfall of gross margin or royalties for the
      Product or to modify the license from exclusive to semi-exclusive in the
      Territory, provided however, in the event that DEXO sells during the ensuing
      90-day period, the difference between the amount actually sold and the minimum
      sales requirement, then ULURU shall not be entitled to receive shortfall in
      Product or modify the license to semi-exclusive. The amount sold to meet the
      minimum sales requirement during such 90-day period, shall be attributed to
      the
      prior year, and not to the year during which such sales are made. For the
      avoidance of doubt, if DEXO makes up the short fall for the annual Minimum
      Sales, then ULURU will not have the right to modify the License and Supply
      Agreement from exclusive to semi-exclusive.





***
      Forecast will be for full calendar year. Launching in part of a calendar year
      will result in an equivalent percentage reduction.** ****





**Unit
      Sales forecast for Major European markets in blister packs of 8:**





**EU**
            **Yr
                1**
            **Yr
                2**
            **Yr
                3**
            **Yr
                4**
            **Yr
                5**EU
            200,000
            400,000
            600,000
            800,000
            1,000,000